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Abstract 
Background: Inflammation is implicated in the development, progression and long-term 
complications of type 2 diabetes (T2DM). Hyperglycemia and visceral adipose tissue, which are 
common in people at risk or diagnosed with T2DM, promote inflammation. Hyperinsulinemia, a 
compensatory mechanism in response to insulin resistance and a result of some pharmacologic 
treatments for T2DM, may also be proinflammatory, which has important implications for 
treatment strategies.  
Purpose: To further understand the effect that diet and its associated relationship with insulin, 
has on inflammation and T2DM outcomes. 
Aim 1: Examines the association between fasting insulin and high sensitivity C-reactive protein 
(hs-CRP), a marker of inflammation, in adults without diabetes, assessing the potential mediating 
role of visceral adipose tissue, operationalized as waist circumference. Using a multinomial 
logistic regression, with hs-CRP divided into three levels of risk and average-risk as the base 
group, in the reduced adjusted model we found that fasting insulin was associated with high-risk 
(RRR = 1.07, p < .001) and low-risk (RRR = 0.91, p < .001) hs-CRP. In the full adjusted model 
also controlling for waist circumference, the low-risk RRR was 0.97 (p < .001) and high-risk 
RRR was 1.02 (p = .002), reflecting the attenuation of 69% and 68% for each group respectively, 
indicating this relationship may be partially mediated by visceral adipose tissue. 
Aim 2: Examines the association between diet (net carbohydrates and total sugar) and white 
blood cell count (WBC), a marker of inflammation, as well as glucose control (glycated 
hemoglobin [HbA1c]). We found a significant association between net carbohydrate intake and 
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WBC (β = 0.001, p = .047) but not between total sugar intake and WBC (β = 0.000, p = .838), 
after adjusting for potential confounders. We did not find a significant association between 
HbA1c and either net carbohydrate (β = 0.001, p = .311) or total sugar (β = -0.000, p = .815), 
after adjusting for potential confounders. 
Aim 3: Examines the effect of a very low-carbohydrate diet (VLC) compared to a Dietary 
Approaches to Stop Hypertension diet (DASH) on fasting insulin, insulin resistance, and 
inflammation in overweight or obese adults with prediabetes or T2DM and hypertension over 4 
months. Overall, the VLC group experienced greater reductions in fasting insulin compared to 
the DASH group (-3.86 µU/mL, p = .027) and Homeostatic Model Assessment 2-Insulin 
Resistance (HOMA2-IR; -0.51, p = .029). However, these effects were no longer significant after 
a Bonferroni adjustment for multiple comparisons. The VLC group experienced greater 
reductions in WBC (-0.72 K/uL, p = .004), which was maintained after a Bonferroni adjustment. 
Reductions in IL-6 approached significance in the DASH vs. VLC group (0.77 pg/mL, p = .070), 
although this was not significant after the Bonferroni adjustment. Statistically significant 
differences between diet groups were not observed for the other tested inflammatory markers.  
Conclusions: This dissertation adds to the evidence that prevention and treatment efforts for 
T2DM may be improved if inflammation is addressed. These results suggest that treatment 
approaches that simultaneously decrease insulin levels while achieving glycemic control may 
provide additional anti-inflammatory effects. 
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Chapter One 
Introduction 
In the United States, diabetes now affects 34 million adults, and an additional 88 million 
have prediabetes. The prevalence of diabetes has increased, and current prevention efforts have 
not reversed the trend (Centers for Disease Control and Prevention, 2017; U.S. Department of 
Health and Human Services, 2020). Additional research is needed to prevent and treat this 
chronic and highly prevalent disease. 
Diet and lifestyle programs targeted to those with prediabetes can prevent or delay the 
progression to type 2 diabetes (T2DM) (Knowler et al., 2002). The Diabetes Prevention Program 
was a three-arm randomized controlled trial that demonstrated it is possible to prevent or delay 
the onset of diabetes with intensive lifestyle modification with a goal body weight loss of 7% 
(Knowler et al., 2002).  
T2DM is a chronic progressive disease. It is a result of insulin resistance, which results in 
progressive dysfunction of beta cells and a concurrent continuing decline in endogenous insulin 
production (Fonseca, 2009). This decline results in an inability to compensate for sustained 
hyperglycemia and the insulin-resistant state (Fonseca, 2009). Current treatment guidelines for 
T2DM focus on glycemic control (American Diabetes Association, 2020). The American 
Diabetes Association (ADA) recommends that an HbA1c of less than 7% be achieved (American 
Diabetes Association, 2020), while similarly, the American Association of Clinical 
Endocrinologists (AACE) recommends that an HbA1c of  less than 6.5% be achieved (Garber et 
al., 2020). Diabetes also increases the risk of many long-term complications including heart 
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disease, stroke, nephropathy, retinopathy and neuropathy. Current treatment efforts are not 
adequately preventing these complications. For example, the prevalence of kidney disease was 
37% in adults aged 18 years and older in 2013-2016 (U.S. Department of Health and Human 
Services, 2020). In addition, diabetes was the seventh leading cause of death in 2017 (U.S. 
Department of Health and Human Services, 2020). Identifying additional treatment strategies 
that can contribute to halting or reversing this progression may improve the morbidity and 
mortality for those diagnosed with this disease. 
Chronic inflammation appears to be involved in the pathogenesis (Donath & Shoelson, 
2011; Rehman et al., 2017), progression (Rehman et al., 2017), and complications (Panee, 2012) 
of T2DM. Pedersen et al. (2015), recently linked insulin with the development of inflammation. 
However, current treatment recommendations do not address inflammation, and frequently use 
medications that increase endogenous insulin production (American Diabetes Association, 2020; 
Garber et al., 2020). Therefore, one method of improving current prevention and treatment 
strategies for prediabetes and T2DM may be to address this chronic inflammation by identifying 
methods that simultaneously decrease glucose levels and inflammation. Inflammatory markers of 
interest include: interleukin 6 (IL-6), interleukin 8 (IL-8), tumor necrosis factor-alpha (TNF-α), 
monocyte chemoattractant protein 1 (MCP-1), high-sensitivity C-reactive protein/C-reactive 
protein (hs-CRP/CRP), and white blood cell count (WBC) at the high end of the normal range. 
An additional consideration with current pharmacological treatment strategies is that they 
are financially burdensome for the individual and for society. Total costs related to diabetes in 
the United States totaled $327 billion in 2017 (U.S. Department of Health and Human Services, 
2020), and the cost of insulin increased 300% between 2002 and 2013 (Kesselheim, Avorn, & 
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Sarpatwari, 2016). Thus, more efficacious and cost-effective treatment options are imperative to 
help prevent significant morbidity and mortality for those impacted with this disease. 
Potential for Dietary Interventions 
Diet may be one way to decrease chronic inflammation observed in T2DM. Dietary 
interventions that simultaneously lower insulin and glucose levels may be more effective at 
decreasing inflammation than solely relying on glycemic control. Therefore, it is justified to  
examine how diet-associated insulin secretion affects inflammation. Previous research suggests 
that fructose or dietary sugar (combination of glucose and fructose) may promote inflammation 
(Aeberli et al., 2011; DiNicolantonio, Mehta, Onkaramurthy, & O'Keefe, 2018). Lowering 
dietary sugar or fructose intake, or carbohydrates in general, may have beneficial effects on 
inflammation, particularly for those who are metabolically compromised (Brymora et al., 2012; 
Hallberg et al., 2018). The ADA does not endorse a specific diet, but rather recommends healthy 
eating patterns (American Diabetes Association, 2020). The ADA recently added low-
carbohydrate diets to the recommended Mediterranean or plant-based diets as examples of 
healthy eating patterns (American Diabetes Association, 2020).  However, the ADA 
recommends long-term dietary studies with clinical outcomes to assess cardiovascular risk and 
safety (Evert et al., 2019). Positive effects may be observed for adults with diabetes following a 
low-carbohydrate ketogenic diet for two years (Athinarayanan et al., 2019). Additionally, the 
standard-of-care dietary treatment for hypertension is the Dietary Approaches to Stop 
Hypertension (DASH) diet (Whelton et al., 2017). However, its effects have not been extensively 
studied in people with prediabetes or T2DM. Therefore, there is a gap in the existing knowledge 
regarding the best diet to simultaneously reduce inflammation as well as glucose levels, an 
approach that could improve outcomes for those diagnosed with diabetes. 
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Impact on Nursing 
In the previously mentioned landmark study, Knowler et al. (2002) demonstrated that it 
was possible to prevent or delay the progression from prediabetes to T2DM by implementing 
lifestyle changes. This research is the basis of the National Diabetes Prevention Program 
(DiBenedetto, Blum, O’Brian, Kolb, & Lipman, 2016), currently led by the CDC (Albright & 
Gregg, 2013). The Center for Medicare and Medicaid Services recently  instituted policies to 
allow for reimbursement of diabetes prevention within a recognized program (Centers for 
Medicare & Medicaid Services et al., 2017). In 2012, the CDC provided funding for 30 certified 
DSME programs to implement the National Diabetes Prevention Program (DiBenedetto et al., 
2016). Diabetes educators consist of  nurses, dieticians, and pharmacists who obtain certification 
in Diabetes Self-Management Education (DSME) programs to provide education to those 
diagnosed with diabetes (DiBenedetto et al., 2016). All the DSME program sites chosen 
exceeded the 5% patient weight loss goal set by the CDC (DiBenedetto et al., 2016). This is 
higher than is generally observed in previous intervention programs implemented in community 
settings (Ely et al., 2017).  As this is a vast resource of qualified educators, it would be prudent 
to utilize this system that is already in place to implement any promising dietary program 
targeted to people with T2DM.  
Purpose 
 The purpose of this dissertation is to further understand the effect that diet and its 
associated reduction of insulin, has on inflammation and diabetes outcomes. To that end, we will 
use a dietary intervention comparing a very-low-carbohydrate (VLC) diet to a Dietary 
Approaches to Stop Hypertension (DASH) diet to study the relationship between insulin, 
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inflammation and metabolic dysfunction. Finally, this research will examine whether a VLC diet, 
or a DASH diet can decrease inflammation.  
Theoretical Approach to Achieve Behavioral Change 
It is important when designing lifestyle programs to consider the sometimes difficult task 
of behavior change. In order to test the efficacy of various dietary treatment strategies, adherence 
to the dietary intervention will be necessary. Utilizing theory derived from evidence-based 
research is one method to design more effective dietary interventions.  
 One concept that has gained attention in assisting people with lifestyle interventions is 
mindfulness. Mindfulness may be defined as a state of awareness and attention to present events 
and experience (Brown, Ryan, & Creswell, 2007). Mindfulness was shown to be an appropriate 
strategy for assisting participants to make behavior change (Brown et al., 2007). Interestingly, 
preliminary research suggests that mindfulness has the capacity to decrease inflammation 
(Brown et al., 2007; Fountain-Zaragoza & Prakash, 2017). Possible mechanisms for the 
preliminary findings may include effects on the hypothalamic-pituitary-adrenal axis or 
sympathetic nervous system (Fountain-Zaragoza & Prakash, 2017). Therefore, participant 
education to increase mindfulness would be an appropriate adjunct to dietary interventions 
utilized to decrease inflammation. 
Specific Aims and Hypotheses 
Aim 1: Examine the association between fasting insulin and high-sensitivity C-reactive protein 
(hs-CRP), a marker of inflammation, using the National Health and Nutrition Examination 
Survey, 2005-2010. I hypothesized a significant positive association between fasting insulin and 
hs-CRP. 
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Aim 2: Examine the association between net carbohydrate and sugar intake on white blood cell 
count at the high end of the normal range (another marker of inflammation), and HbA1c, using 
the National Health and Nutrition Examination Survey, 2011-2016. I hypothesized a significant 
positive association between net carbohydrate and sugar intake, and white blood cell count and 
HbA1c. 
Aim 3: (a) Compare the effects of a very low-carbohydrate diet (VLC) and a Dietary Approaches 
to Stop Hypertension diet (DASH) diet, on fasting insulin, insulin resistance, and inflammatory 
markers. I expect clinically significant improvements in fasting insulin, insulin resistance, and 
inflammatory markers for participants assigned to a VLC diet, compared to lesser improvements 
for those assigned to the DASH diet arm based on suggestive published data (Al-Sarraj, Saadi, 
Calle, Volek, & Fernandez, 2009; Asemi, Samimi, Tabassi, Sabihi, & Esmaillzadeh, 2013; 
Hallberg et al., 2018; Jonasson, Guldbrand, Lundberg, & Nystrom, 2014; Shirani, Salehi-
Abargouei, & Azadbakht, 2013; Steckhan et al., 2016).  
(b) Examine whether changes in fasting insulin associated with VLC or DASH diets influence 
inflammatory markers IL-6, IL-8, TNF-α, MCP-1, hs-CRP, or WBC count. I hypothesized a 
significant positive association between fasting insulin and dietary effect on inflammation. 
  The following chapters will cover a review of the literature, three manuscripts, and final 
conclusions and implications for my dissertation. Chapter Two, Review of Literature on 
Hyperinsulinemia and Inflammation in Prediabetes and Type 2 Diabetes, provides a review and 
synthesis of the scientific literature addressing the association of insulin, inflammation, and 
metabolic disorders including prediabetes and diabetes. Chapter Three, Association Between 
Fasting Insulin and High-Sensitivity C-Reactive Protein Among Adults Without Diabetes: 
NHANES 2005-2010, addresses Aim 1, Chapter Four, Association Between Net Carbohydrate 
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and Sugar Intake on Inflammation and Hemoglobin A1c in Adults with Diabetes, addresses Aim 
2, and Chapter Five, Effects of a Very Low-Carbohydrate Diet Versus a Dietary Approaches to 
Stop Hypertension Diet on Markers of Inflammation, addresses Aim 3. Finally, Chapter Six will 
provide final conclusions, implications for practice, and future research plans. 
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Chapter Two 
Review of Literature on Hyperinsulinemia and Inflammation in Prediabetes and Type 2 
Diabetes 
The following review will cover the research published to March 2019 on 
hyperinsulinemia and inflammation in prediabetes or metabolic syndrome, and type 2 diabetes 
(T2DM). Additional topics covered are the pathophysiologies of hyperinsulinemia, insulin 
resistance, inflammatory markers, and their relation to weight, visceral adipose tissue, 
prediabetes, metabolic syndrome, T2DM, and hypertension. The final topic is on the impact of a 
very low-carbohydrate (VLC) diet, or a Dietary Approaches to Stop Hypertension (DASH) diet, 
on markers of inflammation and the potential role of insulin in this relationship.   
Obesity 
In 2016, 71.2% of adults aged 20 and older were overweight or obese (Centers for 
Disease Control and Prevention, 2017). This has important consequences for metabolic health. 
Metabolic dysfunction, particularly insulin resistance, diabetes, and inflammation, is more likely 
to develop in those who are overweight and obese. The prevalence of diabetes is only 6.2% in 
underweight or normal weight adults, compared to 20.7% of those who are obese (Mendola, 
Chen, Gu, Eberhardt, & Saydah, 2018). Visceral adipose tissue is more metabolically active and 
attracts macrophages, which then secrete proinflammatory cytokines such as IL-1, IL-6, IL-8 and 
TNF-α (Makki, Froguel, & Wolowczuk, 2013). This resulting chronic inflammation is linked to 
the pathogenesis of metabolic disease including T2DM (Donath & Shoelson, 2011).  
Insulin Resistance
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The main actions of insulin are facilitation of glucose and amino acid uptake; synthesis of 
fat, glycogen and protein; suppression of triglyceride, glycogen and protein degradation; and 
increased carbohydrate metabolism at the expense of lipid metabolism (Wilcox, 2005). Insulin 
resistance refers to a decreased sensitivity of cells to the hormonal actions of insulin (Wilcox, 
2005) when higher levels of insulin are observed relative to glucose level (Shanik et al., 2008). 
Furthermore, insulin resistance is more common in those who are overweight or obese, 
particularly when weight is gained in the abdomen (Wilcox, 2005). Compensatory increases in 
insulin typically follow peripheral resistance to insulin action (Wilcox, 2005). Insulin resistance 
has a circular pathway with hyperinsulinemia, in which high levels of insulin further exacerbate 
insulin resistance through the down regulation of insulin receptors (Shanik et al., 2008). In 
addition, resistance to insulin does not develop uniformly throughout the body, which may 
explain why atherogenic effects are observed prior to metabolic effects such as elevated glucose 
levels (Madonna & De Caterina, 2012). Insulin resistance does not progress to T2DM in 
everyone, as some are able to compensate by hyperinsulinemia indefinitely (Tabák, Herder, & 
Kivimäki, 2012).  
The oral disposition index, a product of insulin sensitivity and insulin responses, is a 
method that may predict who will develop T2DM over a period of 10 years (Utzschneider et al., 
2009). It illustrates a hyperbolic pattern between insulin sensitivity and insulin responses in 
subjects with normal β-cell function (Utzschneider et al., 2009). Previous prospective studies 
identified a decline in the disposition index prior to the rise in glucose to diabetic levels 
(Utzschneider et al., 2009). 
Pathology Associated with Hyperinsulinemia 
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A growing body of research finds that hyperinsulinemia is associated with numerous  
pathologies including neuropathy (Kim, McLean, Philip, & Feldman, 2011), cancer 
(Giovannucci, 2007; Micucci, Valli, Matacchione, & Catalano, 2016; Perseghin et al., 2012; 
Vigneri, Goldfine, & Frittitta, 2016; Wysocki & Wierusz-Wysocka, 2010), stroke (Lindahl et al., 
2000) and heart disease (Cabrera De León et al., 2015; Despres et al., 1996; Mitsuhashi et al., 
2011). Insulin is necessary for the optimal growth of some cancers in vitro (Vigneri et al., 2016). 
Medications targeting a reduction in insulin levels, such as metformin, improve cancer outcomes 
(Becker, Dossus, & Kaaks, 2009; Wysocki & Wierusz-Wysocka, 2010). It is possible that 
hyperinsulinemia is negatively impacting all of these pathologies through a similar pathway.  
Additional research is needed to understand the underlying temporal precedence and 
mechanisms behind the association between insulin and metabolic pathologies.  
Hyperinsulinemia and Obesity 
The carbohydrate-insulin model of obesity posits that the high-glycemic dietary load is 
responsible for obesity (Ludwig & Ebbeling, 2018). It suggests that a diet of highly processed 
carbohydrates produces hormonal responses that promote weight gain, exacerbate hunger, and 
lower energy expenditure (Ludwig & Ebbeling, 2018). In a recent study examining weight 
maintenance following a 12% weight loss, participants were assigned to one of three diets 
varying in carbohydrate content between 20 and 60%, to maintain weight loss. The sample was 
stratified by postprandial insulin concentration 30 minutes following a glucose load. There was a 
positive association between the amount of carbohydrate restriction and energy expenditure. 
With every 10% decrease in carbohydrate intake, participants expended an additional 52 
kcal/day. There was an inverse relationship between postprandial insulin levels and energy 
expenditure, so that participants in the highest insulin tertile before weight loss had expended an 
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additional 308 to 478 kcal/day (intention-to-treat versus per protocol) when consuming the low 
carbohydrate versus the high carbohydrate diet. The increased energy expenditure observed with 
carbohydrate restriction supports the hypothesis that insulin elevations promote weight gain by 
suppressing energy expenditure (Ebbeling et al., 2018). 
Hyperinsulinemia may be a necessary condition for development of obesity. Genetically 
modified mice rendered incapable of developing hyperinsulinemia, but maintaining euglycemia, 
lost the capacity to become obese (Mehran et al., 2012). Additionally, bariatric surgery 
frequently induces diabetes remission within one week of surgery and before significant weight 
loss occurs (Kelly et al., 2014). Hyperinsulinemia (based on fasting insulin) resolved within days 
of surgery, but insulin resistance had not normalized over three months following surgery (Kelly 
et al., 2014).  
Hyperinsulinemia’s Role in Metabolic Disease 
Plausible biologic mechanisms for hyperinsulinemia’s role in the development of disease 
may be mediated through its proliferative, proinflammatory, and insulin-resistance promoting 
activation of Ras (Madonna & De Caterina, 2012). Ras GTPases are a family of proteins 
involved in regulating molecular signals in eukaryotic cells to maintain homeostasis (Díez, 
Sánchez-Jiménez, & Ranea, 2011; Mor, Aizman, George, & Kloog, 2011). Ras regulates these 
signals by acting as a molecular switch for a number of functions, including activating immune 
cells and phosphoinositide 3-kinases (PI3k). Activated PI3K phosphorylates IkB kinase (IKK). 
This in turn activates NF-kB, an agent that may impair insulin signaling (Mor et al., 2011).  
Insulin also has the capacity to increase production of plasminogen activator inhibitor 
type 1 (PAI-1), endothelin, and expression of surface adhesion molecules (Madonna & De 
Caterina, 2012). The increased production of PAI-1 protein can have pathologic consequences 
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due to its role in thrombosis. PAI-1 circulates in the bloodstream and inhibits serine proteases 
such as tissue plasminogen activator (t-PA), which is necessary to dissolve fibrin clots. Increased 
levels of PAI-1 have been associated with venous thrombosis, pulmonary embolism, and 
atherosclerosis (Schneider & Sobel, 2012). Endothelin is a proinflammatory vasoconstrictive 
peptide produced by the vascular endothelium (Horinouchi et al., 2016). It has been implicated in 
the development of insulin resistance in skeletal muscle (Horinouchi et al., 2016). 
 Interactions between monocytes and endothelial cells are also involved in atherosclerosis 
(Madonna, Pandolfi, Massaro, Consoli, & De Caterina, 2004). For example, vascular cell 
adhesion molecule-1 (VCAM-1), expressed in endothelial cells, promotes the attachment of the 
monocyte to the arterial wall. Hyperinsulinemia promotes the expression of VCAM-1 in vitro. 
As the expression of this molecule is associated with atherosclerosis, this may help to explain the 
higher rates of heart disease observed in subjects with metabolic disease before the onset of 
T2DM (Cabrera De León et al., 2015; Després et al., 1996; Madonna et al., 2004; Mitsuhashi et 
al., 2011). 
Inflammation 
Inflammation is a novel potential target for prevention, treatment, and improvement of 
diabetes outcomes. The etiology of chronic inflammation likely involves multiple factors related 
to diet, hyperinsulinemia, stress, and obesity. In addition, a number of inflammatory cytokines 
have been implicated in the development of chronic inflammation including IL-6, IL-8, TNF-α, 
MCP-1, hs-CRP, and a WBC count at the higher end of the normal range.  
Proinflammatory Markers 
Interleukin 6 
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The proinflammatory cytokine IL-6 is predominantly produced by adipocytes, as well as 
monocytes, endothelial cells, fibroblasts, skeletal muscle and macrophages (Makki et al., 2013; 
Rehman et al., 2017). Part of its inflammatory action is through controlling differentiation, 
migration, proliferation, and neutrophilic and β cell apoptosis (Rehman et al., 2017). IL-6 also 
impairs intracellular signaling through suppressors of cytokine signaling 3 (SOCS-3) and Janus 
kinases/signal transducers and activators of transcription (JAK/STAT) (Rehman et al., 2017). 
SOCS-3 proteins are expressed when stimulated by cytokines (Barclay, Anderson, Waters, & 
Curlewis, 2007). These proteins interact with the JAK/STAT pathway as a negative regulator of 
gene expression (Barclay et al., 2007). For instance, SOCS-3 acts as a negative regulator of the 
leptin receptor and thus interferes with leptin’s role in energy regulation, energy expenditure, and 
satiety (Gurzov, Stanley, Pappas, Thomas, & Gough, 2016). In obese individuals these leptin 
actions become dysregulated due to leptin resistance despite high leptin levels. Hyperleptinemia 
is implicated in β-cell dysfunction (Gurzov et al., 2016). IL-6 is involved in development of 
insulin resistance and T2DM (Wang et al., 2013). In part, it does so through impairment and 
destruction of beta cells and progression to T2DM (Rehman et al., 2017).  
Interleukin 8  
IL-8 is a proinflammatory chemokine secreted by adipocytes, monocytes, macrophages, 
T-lymphocytes, endothelial and epidermal cells (Cimini et al., 2017). It is involved in the 
initiation and maintenance of the inflammatory process within the adipose tissue (Cimini et al., 
2017). IL-8 levels are higher in diabetic subjects compared with controls and are associated with 
reduced glycemic control (Cimini et al., 2017). 
Tumor Necrosis Factor-α  
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TNF-α is secreted by adipocytes (Rehman & Akash, 2016) and macrophages (Kahn, 
Hull, & Utzschneider, 2006). Elevated levels of TNF-α in obese subjects alter the action of 
insulin by activating the Jun NH2-terminal kinase (JNK) and nuclear factor kappa-B (NF-kB) 
pathways (Rehman & Akash, 2016). The JNK family comprises JNK1, JNK2 and JNK 3, of 
which JNK1 and JNK2 affect insulin signaling (Pal, Febbraio, & Lancaster, 2016). JNKs are 
activated in response to stress signals, one of which is TNF-α (Pal et al., 2016). NF-kB is a 
mediator of inflammation but under normal conditions is inactive in the cytoplasm (Nandipati, 
Subramanian, & Agrawal, 2017). Activation of JNK and NF-kB results in phosphorylation of 
insulin receptor substrate-1 (IRS1) at serine 307 which impairs insulin signaling (Pal et al., 
2016). The activation of the JNK and NF-kB pathways are associated with the development of 
insulin resistance (Kaneto, 2005; Nandipati et al., 2017). 
Monocyte Chemoattractant Protein-1  
MCP-1 is a chemokine produced from hypertrophied adipocytes and thought to be 
responsible for some of the initial macrophage infiltration into adipose tissue (Rehman & Akash, 
2016). MCP-1 increases during hyperglycemia and continues to be produced by adipose tissue to 
act in a proinflammatory capacity (Panee, 2012). Its role in the development of obesity, insulin 
resistance and diabetes was reviewed by Panee (2012).  
High-Sensitivity C-Reactive Protein  
Hs-CRP is an acute-phase reactant produced in the liver and a sensitive marker of low-
grade inflammation (Wang et al., 2013). A meta-analysis completed on prospective studies found 
a significant association between CRP and risk of T2DM (Wang et al., 2013).  
White Blood Cells 
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Higher levels of leukocytes, lymphocytes and neutrophils within the normal range have 
been observed in obese subjects with insulin resistance when compared to obese subjects without 
it (Ryder et al., 2014).  Lymphocytes are positively correlated with insulin levels (Ryder et al., 
2014). Subjects in the upper quartiles of total leukocyte count display higher rates of metabolic 
syndrome when compared to the lowest quartile (Babio et al., 2013). In the longitudinal 
PREDIMED study, subjects who developed metabolic syndrome during the follow-up period had 
significantly higher leukocyte counts at baseline (Babio et al., 2013). Finally, a higher WBC 
count was found in a systematic review and meta-analysis to be significantly associated with a 
higher risk of T2DM (Gkrania-Klotsas et al., 2010).  
Inflammation and Insulin 
Insulin is associated with the development of inflammation (Pedersen et al., 2015). This 
was demonstrated by reducing insulin levels by about 40% in obese mice treated with diazoxide 
or streptozotocin. In spite of no significant changes in body weight, and with free access to water 
and food (60% of calories from lipids), decreasing insulin levels reduced the number of 
macrophages and inflammatory markers in the adipose tissue.  
Infusion of insulin under euglycemic conditions in lean mice stimulated the production of 
cytokines in the adipose tissue (Pedersen et al., 2015). Infusion of insulin via osmotic 
minipumps, shifted the macrophage balance from anti-inflammatory M2 to proinflammatory M1 
type (Kumar et al., 2018). The shift in macrophage balance was mediated by inducible nitric 
oxide synthetase (iNOS) leading to extracellular matrix (ECM) build-up and insulin resistance 
(Kumar et al., 2018). iNOS is an enzyme that generates nitric oxide from L-arginine, an amino 
acid (Lirk, Hoffmann, & Rieder, 2002). The ECM is the space outside the cell that undergoes 
remodeling as a result of injury (Williams, Kang, & Wasserman, 2015). Reducing insulin 
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decreased adipose tissue inflammation along with improved insulin sensitivity (Kumar et al., 
2018). Thus obesity, mediated by insulin, can lead to changes in cellular signaling leading to 
insulin resistance (Williams et al., 2015). 
When insulin was used to treat T2DM, it resulted in weight gain, an influx of 
macrophages, and inflammation (Jansen et al., 2013). However, this influx of macrophages was 
independent of weight gain, although the levels of proinflammatory cytokines were higher in 
those who had gained more than 4% body weight (Jansen et al., 2013). 
Metabolic Syndrome 
Diagnostic criteria for metabolic syndrome include dysglycemia, elevated blood pressure, 
elevated triglyceride levels, low levels of high-density lipoprotein cholesterol and central obesity 
which place people at increased risk for cardiovascular disease and diabetes (Alberti et al., 
2009). The presence of three of these risk factors is required for a diagnosis of metabolic 
syndrome. International cut-off points were agreed upon for all risk factors with the exception of 
waist circumference. They are for triglycerides 150 mg/dL or higher, for HDL-C, less than 40 
mg/dL for males or less than 50 mg/dL for females, for blood pressure 130 mmHg or higher 
systolic, or 85 mmHg or higher diastolic, and for fasting glucose 100 mg/dL or higher. Taking 
medication to reduce levels below the cut-off constitutes a diagnostic risk factor. The cut-off 
point for waist circumference in the United States is 102 cm or more for males and 88 cm or 
more for females. Waist circumference cut-off points based on race or ethnicity, rather than 
gender alone, may more accurately define risk. 
Prediabetes 
Prediabetes is a component of metabolic syndrome. A diagnosis of prediabetes is made 
based on a fasting glucose between 100 and 125 mg/dL, a two-hour blood glucose concentration 
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between 140 and 199 mg/dL post 75-gram oral glucose tolerance test, or a hemoglobin A1c 
(HbA1c) between 5.7% and 6.4% (Wilson, 2017). Importantly, only some subjects develop 
hyperglycemia and progress to T2DM, while others compensate for insulin resistance 
indefinitely.  
In the previously mentioned Diabetes Prevention Program trial, participants were 
randomized to 850 mg of metformin twice daily, a diet and exercise intervention, or a placebo, 
with a goal of achieving a 7% weight loss (Knowler et al., 2002). The intensive lifestyle arm 
included a 16-lesson curriculum that provided education about a low-fat diet, exercise, and 
behavior modification. Over the average follow-up of 2.8 years, the lifestyle intervention 
decreased the incidence of diabetes by 58%, and the metformin arm decreased it by 31%, 
compared to the placebo arm. In addition, weight loss was greatest in the lifestyle arm with 50% 
of participants losing at least 7% of their body weight at 24 weeks (end of guidance period), 
although this diminished to 38% of participants at the end of the study (Knowler et al., 2002). 
This suggests that during this trial, there was some propensity for participants to regain weight. 
Moreover, weight loss achieved in community-based programs tend to be less than that achieved 
during research trials (Ali, Echouffo-Tcheugui, & Williamson, 2012). 
Hypertension 
Hypertension also is a component of metabolic syndrome. Guidelines were recently 
revised lowering the diagnostic criteria so that elevated blood pressure (previously termed 
prehypertension) is defined by systolic between 120 and 129 mmHg and diastolic by less than 80 
mm Hg; stage 1 hypertension is defined by 130 -139 mmHg systolic or by diastolic between 80 
and 89 mmHg; and stage 2 is defined by systolic of 140 mmHg or greater or by diastolic 90 
mmHg or greater (Whelton et al., 2017). The effect of insulin on blood pressure is as yet 
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uncertain (Brands & Manhiani, 2012). More recent research suggests that hyperinsulinemia may 
raise blood pressure in the presence of concomitant hyperglycemia (Brands & Manhiani, 2012). 
Type 2 Diabetes 
A diagnosis of T2DM is made when fasting glucose has reached 126 mg/dL or higher, 
HbA1c has risen to 6.5% or higher, or a blood glucose of 200 mg/dL or higher two hours after an 
oral glucose tolerance test. T2DM develops when the body fails to compensate for insulin 
resistance (Alejandro, Gregg, Blandino-Rosano, Cras-Méneur, & Bernal-Mizrachi, 2015). The 
loss of β-cells, and their failure to maintain mass and function, leads to relative insulin deficiency 
that are the key components to the development of T2DM (Chen, Cohrs, Stertmann, Bozsak, & 
Speier, 2017). Previous studies suggest that the propensity to develop metabolic disease may 
start with intrauterine exposure to undernutrition, overnutrition, or metabolic disease (Dabelea et 
al., 2000; Dabelea et al., 2008; Garofano, Czernichow, & Bréant, 1997; Gluckman, Hanson, 
Cooper, & Thornburg, 2008; Patti, 2013). No clear genetic determinants of T2DM have been 
established (Alejandro et al., 2015). However, epigenetic changes may be in part responsible for 
the dramatic rise in T2DM (Guenard et al., 2013; Patti, 2013). A recent comprehensive review 
by Alejandro et al. (2015) explains the role of β-cell dysfunction as a primary determinant in the 
development and progression of T2DM. According to Alejandro, β-cells are susceptible to 
glucolipotoxicity and proinflammatory cytokines. The chronic exposure to elevated glucose 
levels, in combination with elevated free fatty acids, both markers of insulin resistance in liver 
and adipose tissue, are involved in inducing β-cell failure. Endoplasmic reticulum (ER) stress is 
also involved in β-cell failure and the progression of T2DM. The ER is the site where proinsulin 
is folded to become the final protein insulin. The ER is sensitive to stressors, such as 
proinflammatory cytokines, which may lead to the accumulation of unfolded proteins. This sets 
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off the unfolded protein response (UPR), which while initially protective, upon chronic signaling 
can result in further β-cell failure through apoptosis. Finally, hyperglycemia may lead to β-cell 
failure through oxidative stress. Hyperglycemia sets off a cascade of events culminating in an 
excess of reactive oxygen species in the islet leading to β-cell dysfunction.  
Inflammation and Long-term Complications 
Inflammation is involved not only in the pathogenesis of T2DM, but also in its long-term 
complications. Inflammation likely contributes to the development of complications related to 
diabetes, and decreasing inflammation may improve long-term outcomes (Panee, 2012). 
Hyperglycemia may increase the release of MCP-1 leading to the development of nephropathy, 
retinopathy and insulitis (inflammation of the islets of Langerhans leading to the destruction of 
beta cells). Inflammation is therefore important to investigate as many individuals with T2DM 
are suffering from long-term complications. In addition, cytokines may play an important role in 
inflammation. In the ADVANCE trial, cytokine IL-6 was an independent predictor of 
macrovascular complications and death in people with T2DM (Lowe et al., 2014). IL-8 also is an 
independent predictor of all-cause mortality in those with acute coronary syndrome (Cavusoglu 
et al., 2015). This may have important implications for those diagnosed with T2DM, as they are 
at increased risk of heart disease.  
Effect of Diet on Insulin, Inflammatory Markers, and Weight 
Approaches to decrease inflammation in adults with prediabetes or T2DM have included 
medications, alterations in diet, and plant extracts or other supplements such as vitamin D (Dutta 
et al., 2014; Panee, 2012). Diets have shown promise to influence fasting insulin, inflammation 
and weight loss, although dietary interventions to decrease markers of inflammation have met 
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with varying levels of success. Therefore, a research focus on identifying the optimal diet may 
have an important role in halting or reversing the progression of T2DM.  
Sugar or carbohydrate restriction in general are frequently used in dietary intervention 
trials. Trials using low-carbohydrate (LC) or very low-carbohydrate (VLC) diets (Forsythe et al., 
2008; Hallberg et al., 2018; Hu et al., 2013; Jonasson, Guldbrand, Lundberg, & Nystrom, 2014) 
reported greater reductions in inflammatory markers than DASH trials (Asemi, Samimi, Tabassi, 
Sabihi, & Esmaillzadeh, 2013). To our knowledge, trials to date have not directly compared 
these two diets in a population with prediabetes or T2DM. Furthermore, while high fructose 
intake, such as by drinking sugar-sweetened beverages has been associated with metabolic 
disease (Aeberli et al., 2011; DiNicolantonio, Mehta, Onkaramurthy, & O'Keefe, 2018; Rutledge 
& Adeli, 2007), few trials have utilized dietary interventions solely based on lowering fructose 
intake (Brymora et al., 2012; Maier et al., 2011). Furthermore, a reduction of caloric intake is 
also observed when trying to lower fructose intake (Maier et al., 2011).  
A version of carbohydrate modification was observed in the DIETFITS trial, a 
randomized clinical trial that included 609 overweight or obese adults (BMI 28-40) with diabetes 
(Gardner et al., 2018; Stanton et al., 2017). This trial compared weight loss associated with a 
“healthy” (LC) diet or a “healthy” low-fat (LF) diet. This trial also sought to investigate whether 
insulin levels 30 minutes after a glucose challenge influenced the effect of the diet. Both diets 
were low in high-glycemic carbohydrates and sugar by maximizing vegetable intake and 
minimizing intake of added sugars, refined flours, and trans fats. In addition, the emphasis was to 
focus on nutrient-dense whole foods prepared at home whenever possible. The initial 8-week 
phase of the diet had participants restrict either fat ( LF arm) or carbohydrate ( LC arm), 
followed by adding back foods with no set upper limit. Subjects were asked to monitor how it 
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affected their weight-loss progress and adjust the level of restriction accordingly (maintain, 
restrict, or increase). Carbohydrate intake was 48% in the  LF arm and 30% in the  LC arm at 12-
months. In this trial, where the instruction was to eliminate sugars and refined carbohydrates in 
both diets, weight loss did not differ among arms and insulin levels did not alter the effect of 
diet.  
Finally, pharmacotherapy that blocks the activity of specific proinflammatory cytokines 
offers a unique insight into decreasing inflammation as a treatment approach as the positive 
effects are not associated with weight loss. Decreasing inflammation produced beneficial effects 
independently of reduced weight or glucose levels, and therefore is a promising area of research 
to improve outcomes for individuals with diabetes (Dinarello, Simon, & Van Der Meer, 2012; 
Fleischman, Shoelson, Bernier, & Goldfine, 2008; Larsen et al., 2007). 
Low-carbohydrate (LC) diets  
LC diet is an umbrella term used to identify all carbohydrate-restricted diets from LC to 
very-low-carbohydrate (VLC) (also known as ketogenic) diet. The level of non-fiber 
carbohydrate intake in a LC diet varies from 20-35 grams per day up to 40% of calories from 
carbohydrate. VLC diets fall at the low end of this spectrum, as carbohydrates are restricted to 
the point at which the body begins using ketones as a fuel source. VLC diets are generally 
described as high in fat, moderate in protein, and low in carbohydrates. Previous studies provide 
empirical support for the use of VLC diets in T2DM by documenting weight loss, lowered 
glucose, and lower levels of inflammatory markers (Hallberg et al., 2018; Jonasson et al., 2014; 
Saslow et al., 2014; Saslow et al., 2017; Seshadri et al., 2004). A biological explanation for these 
beneficial effects in studies using VLC diets in adults with T2DM, is their ability to lower insulin 
levels and thus access adipose tissue for fuel, where beta-hydroxybutyrate is the byproduct of 
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hepatic oxidation of free fatty acids (Hallberg et al., 2018). Furthermore, these diets generally 
recommend moderate protein content, which generally is between 80-120g per day (as 
recommended by the Institute of Medicine) (Trumbo, Schlicker, Yates, & Poos, 2002), with the 
remaining calories from fat. Dietary fat will vary greatly based on the phase of the diet (Volek & 
Phinney, 2011). In the weight-loss phase, body fat provides a source of energy for fuel, and 
dietary fat may be eaten to satiety (Volek & Phinney, 2011). However, as weight-loss goals are 
achieved, dietary fat consumption is increased. During the weight-maintenance phase of VLC 
diet, dietary fat intake comprises approximately 65%-70% of calories (Volek & Phinney, 2011).  
Meals generally include animal foods, cheeses, eggs, fats (butter, oil), nuts, seeds and low-
carbohydrate vegetables. 
Dietary Approaches to Stop Hypertension diet (DASH) 
The DASH diet involves lowering sodium to less than 2300 milligrams per day by 
focusing on foods high in potassium, magnesium, and calcium. Carbohydrate intake of a DASH 
diet is typically around 55% of calories while fat intake is limited to 20-30% of calories (Chiu et 
al., 2016). Furthermore, the diet encourages fruits and non-starchy vegetables, lean meats and 
fish, whole grains and low-fat dairy while limiting foods high in saturated fat, oil and sugar 
(Sacks et al., 2009). 
Effects on Insulin of Low-Carbohydrate, Very Low-Carbohydrate and Ketogenic Diets  
Insulin is a necessary hormone for increased metabolism of glucose, removal of glucose 
from circulation through facilitation of carbohydrate metabolism, stimulation of peripheral 
glucose uptake, and use of glucose as a substrate for synthesis of carbohydrates and fat. By virtue 
of their low dietary carbohydrate load, VLC diets are theorized to reduce insulin levels. This has 
been corroborated in multiple studies implementing carbohydrate restriction from a high of 30% 
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of calories to levels low enough to result in nutritional ketosis. Participants used in these studies 
have ranged from healthy to those with T2DM. Regardless of the measures of insulin 
concentration used, including fasting, 24-hour mean, 12-hour, 4-hour postprandial, or area under 
the postprandial curve, all studies reported a decrease in insulin level (Bazzano et al., 2014; 
Boden, Sargrad, Homko, Mozzoli, & Stein, 2005; Essah, Levy, Sistrun, Kelly, & Nestler, 2007; 
Hallberg et al., 2018; Hayes et al., 2007; Lin & Borer, 2016; Ratliff, Mutungi, Puglisi, Volek, & 
Fernandez, 2009). This reduction of insulin may increase the anti-inflammatory effects of a diet. 
Effects on Inflammation of Low-Carbohydrate, Very Low-Carbohydrate and Ketogenic 
Diets  
A VLC diet was found to be effective at decreasing inflammatory markers in several 
studies (Al-Sarraj, Saadi, Calle, Volek, & Fernandez, 2009; Forsythe et al., 2008; Hallberg et al., 
2018; Hu et al., 2013; Jonasson et al., 2014; Seshadri et al., 2004). This effect was associated 
with a decrease in several inflammatory markers: IL-6 (Forsythe et al., 2008; Hu et al., 2013; 
Jonasson et al., 2014), IL-8 (Forsythe et al., 2008; Hu et al., 2013), TNF-α (Al-Sarraj et al., 2009; 
Forsythe et al., 2008; Hu et al., 2013), MCP-1 (Forsythe et al., 2008; Hu et al., 2013), and WBC 
(Bhanpuri et al., 2018). Forsythe et al. (2008) and Jonasson et al. (2014) observed anti-
inflammatory effects independent of weight loss. The association between low-carbohydrate 
diets and a decrease in CRP among adults with metabolic syndrome was not confirmed in a 
recent meta-analysis (Steckhan et al., 2016). The negative outcome could be due to the inclusion 
of only three low-carbohydrate studies which varied in carbohydrate content and limitations in 
study designs.  
Effects on Weight of Low-Carbohydrate, Very Low-Carbohydrate and Ketogenic Diets 
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LC diets appear to be an effective tool for weight loss (Forsythe et al., 2008; Gardner et 
al., 2007; Hallberg et al., 2018; Meng et al., 2017; Saslow et al., 2014). Possible mechanisms 
include reduced insulin accompanied with increased energy expenditure, decreased appetite, and 
preservation of lean mass during weight loss. Weight loss among overweight premenopausal 
women at 12 months was significantly greater in the Atkins group (the lowest carbohydrate 
intake diet) when compared to the Zone, Ornish and LEARN diet groups (Gardner et al., 2007). 
A secondary analysis of these data signaled insulin as critical for the additional weight loss. 
When comparing the Atkins (low-carbohydrate) diet to the Ornish (very low-fat) diet individuals 
with the highest fasting insulin levels at baseline experienced greater weight loss when assigned 
to the low-carbohydrate group, whereas those with the lowest fasting insulin level at baseline lost 
similar amounts of weight when assigned to either group (Gardner et al., 2008). 
LC diets may affect appetite by means of reduced insulin (Alsaadi & Van Vugt, 2015) or 
increased ketones (Gibson et al., 2015). While insulin inhibits appetite in the postprandial state 
by acting on appetite regulation centers of the brain, this relationship is blunted in insulin 
resistance (Alsaadi & Van Vugt, 2015). One well-controlled inpatient trial documented the 
spontaneous reduction in calories observed with  LC diets. Nutrient intake and multiple 
metabolic measurements were monitored closely for one week prior to admission while 
following their usual diet. Participants were then admitted to a metabolic ward and fed a LC 
which limited carbohydrates to approximately 21 grams per day and without restrictions on 
protein or fat, for two weeks. Caloric intake spontaneously decreased from an average of 3,111 
before the diet intervention to 2,164 while following the VLC diet while insulin sensitivity 
improved by 75% (Boden et al., 2005). VLC or ketogenic diets and very low-calorie diets appear 
to have appetite suppressing effects due to the production of ketones (Gibson et al., 2015). 
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Metabolic changes that occur during weight loss lead to increased hunger and decreased 
energy requirements which can promote weight regain (Melby, Paris, Foright, & Peth, 2017). A 
recent review on the effects of insulin sensitivity during weight loss and weight regain found that 
improvements in insulin sensitivity did not predict weight regain (Strohacker, McCaffery, 
Maclean, & Wing, 2014). However, previous research is inconsistent. Other trials suggest that 
the choice of diet followed during the weight-loss maintenance period is an essential component 
of preventing weight regain, particularly for those that are metabolically compromised (Hjorth et 
al., 2017). In these trials, overweight participants with elevated glucose levels were better able to 
maintain weight loss when following a low glycemic load or a high fiber diet (Hjorth et al., 
2017). Further research is needed to understand appetite regulation and its effect on the 
likelihood of regaining weight. 
It has been hypothesized that LC diets also may allow a greater proportion of weight loss 
from adipose tissue than from the lean mass. Studies have demonstrated a higher fat-specific 
weight loss while lowering carbohydrate content and/or glycemic load (Goss et al., 2013; 
Krieger, Sitren, Daniels, & Langkamp-Henken, 2006; Volek, Quann, & Forsythe, 2010; Volek et 
al., 2004; Volek et al., 2002). However, a recent position statement by the International Society 
of Sports Nutrition, finds that a specific macronutrient composition does not provide additional 
benefit to maintaining lean mass while losing weight (Aragon et al., 2017). Thus, this area 
remains controversial and requires additional research. 
Effects on Insulin and Inflammation of Dietary Approaches to Stop Hypertension Diet  
Two meta-analyses examined the use of the DASH diet on fasting insulin (Shirani, 
Salehi-Abargouei, & Azadbakht, 2013), insulin resistance (Shirani et al., 2013), and 
inflammation (Soltani, Chitsazi, & Salehi-Abargouei, 2018). Shirani et al. (2013) found that a 
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DASH diet could significantly reduce fasting insulin, but not insulin resistance. Furthermore, the 
DASH diet reduced CRP, but was only significant when DASH was compared to a usual diet 
and not to an alternative healthy diet (Soltani, Shirani, Chitsazi, & Salehi-Abargouei, 2016). 
Therefore, it is unclear how the DASH diet will compare to the positive health effects observed 
in people following a VLC diet. 
Effects of Weight Loss on Inflammation  
Since VLC diets frequently produce weight loss, and weight loss is known to decrease 
the inflammatory marker CRP (Selvin, Paynter, & Erlinger, 2007), it is important to examine the 
effect on inflammation independently of weight changes. As metabolically active abdominal fat 
is responsible for the production of inflammatory cytokines, and it is generally reduced in size on 
VLC diets (Bazzano et al., 2014; Harvey et al., 2019; Volek et al., 2004; Volek et al., 2002) thus 
providing a potential biologic mechanism for the reduction of inflammation by VLC diets. 
However, reduction in some inflammatory markers utilizing a VLC diet appears to be 
independent of weight loss in some studies (Forsythe et al., 2008; Jonasson et al., 2014). 
Effect of Using Mindfulness in Dietary Interventions  
Mindfulness interventions have many positive benefits, which include decreasing 
inflammation in general (Brown, Ryan, & Creswell, 2007; Fountain-Zaragoza & Prakash, 2017; 
Malarkey, Jarjoura, & Klatt, 2013) and specific proinflammatory markers NF-kB and CRP, in 
particular (Black & Slavich, 2016). They also may change eating behavior (Daubenmier et al., 
2011; Mason et al., 2016). Therefore, this may be a promising intervention to potentially 
augment anti-inflammatory effects. 
Treatment Cost 
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Current treatment approaches generally include medications, diet, and exercise 
(American Diabetes Association, 2020). Cost may be an important consideration in selection of  
an optimal treatment approach for diabetic patients to reduce hyperglycemia and inflammation. 
Among adults in the US, 15.6% have an HbA1c greater than 9%, which is well above the less 
than 7% recommended by the ADA (Centers for Disease Control and Prevention, 2017). Newer 
classes of drugs may be prohibitively expensive when generic options are not yet available, and 
the price increases may leave many Americans unable to afford their medications. In fact, the 
ADA now recognizes this and recommends that affordability now be considered when choosing 
a treatment approach (American Diabetes Association, 2020). Therefore, identifying the most 
effective and less costly dietary approaches may help individuals reduce their reliance on 
medications. 
Conclusions 
The association between hyperinsulinemia and numerous chronic diseases warrants 
further research on the relationship, mechanism, and temporal reference between these variables. 
Hyperinsulinemia is difficult to study independently of insulin resistance. One current hypothesis 
is that the current high-glycemic load of diet may be a primary driver of hyperinsulinemia and 
subsequent obesity and chronic disease (Ludwig & Ebbeling, 2018). A growing body of research 
is providing insight into the biologic mechanisms behind hyperinsulinemia’s role in the 
development of chronic disease (Madonna & De Caterina, 2012). Inflammation is an important 
variable in the pathogenesis (Donath & Shoelson, 2011) and progression (Rehman et al., 2017) 
of T2DM, as well as its long-term complications (Panee, 2012). While insulin also appears to 
have an independent role in the development of inflammation (Pedersen et al., 2015), its role in 
the development and perpetuation of chronic inflammation is not completely understood. 
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Furthermore, the use of exogenous insulin often confounds research outcomes, as it is often used 
to achieve glycemic goals, a standard of care in diabetes treatment (American Diabetes 
Association, 2020). 
VLC diets appear to decrease inflammation (Al-Sarraj et al., 2009; Forsythe et al., 2008; 
Hallberg et al., 2018; Hu et al., 2013; Jonasson et al., 2014; Seshadri et al., 2004). Previous 
research using VLC diet interventions have frequently compared them to low-fat diets (Forsythe 
et al., 2008; Hu et al., 2013; Jonasson et al., 2014; Seshadri et al., 2004). Since a DASH diet is 
frequently recommended by American Diabetes Association and the American Heart Association 
(American Diabetes Association, 2018; Sacks et al., 2017) as a way of reducing metabolic 
diseases, it is important to find out how a VLC diet compares to a DASH diet with respect to 
markers of inflammation. Therefore, this research will seek to fill the knowledge gap by 
comparing the effects of a VLC diet versus a DASH  on fasting insulin and markers of 
inflammation to see whether there is any relationship between insulin and inflammation.
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Chapter Three 
Association Between Fasting Insulin and High-Sensitivity C-Reactive Protein Among 
Adults Without Diabetes: NHANES 2005-2010 
Type 2 diabetes (T2DM) affects over 34 million U.S. adults and an additional 88 million 
U.S. adults are estimated to have prediabetes (U.S. Department of Health and Human Services, 
2020). T2DM is characterized by hyperglycemia and insulin resistance, which occurs when cells 
become less responsive to the glucose-lowering actions of insulin (Wilcox, 2005). 
Hyperglycemia creates a proinflammatory state through multiple mechanisms including altered 
function of the innate immune system, decreased vascular dilation and its increased permeability, 
and increased production of proinflammatory cytokines (Jafar, Edriss, & Nugent, 2016). It is also 
partly responsible for the long-term complications of T2DM (U.S. Department of Health and 
Human Services, 2020).  
Glycemic control is a focus of current T2DM treatment guidelines (American Diabetes 
Association, 2020). There are currently several classes of glucose-lowering medications for the 
treatment of T2DM including biguanides, sulfonylureas, meglitinides, thiazolidinediones (TZD), 
dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose cotransporter (SGLT2) inhibitors, and 
glucagon-like peptide-1 receptor agonists (GLP-1s) (Chaudhury et al., 2017). Glycemic control 
appears to be more effective at preventing microvascular complications such as retinopathy, 
nephropathy, and neuropathy than macrovascular outcomes such as cardiovascular disease (Ali 
et al., 2019). 
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Insulin resistance develops more frequently in those who are overweight or obese, 
particularly when weight is gained in the abdomen (Wilcox, 2005). Insulin resistance results in 
compensatory increases in insulin, leading to hyperinsulinemia which is defined by insulin 
secretion higher than normal relative to blood glucose (Thomas, Corkey, Istfan, & Apovian, 
2019). However, there is debate about the optimal range of insulin, and it varies based on fasting 
versus postprandial status (Crofts, Zinn, Wheldon, & Schofield, 2015). 
There is substantial evidence that inflammation is involved in the development, 
progression, and long-term complications of T2DM, and that visceral adipose tissue and 
proinflammatory cytokines play a key role in them (Donath & Shoelson, 2011; Panee, 2012). 
Visceral adipose tissue is far more detrimental compared to fat in other locations in the 
development of chronic inflammation. It is metabolically active and attracts macrophages, which 
then secrete proinflammatory cytokines such as interleukin-1 (IL-1), interleukin-6 (IL-6), 
interleukin-8 (IL-8) and TNF-α (Makki, Froguel, & Wolowczuk, 2013). Therefore, decreasing 
inflammation may also be an important treatment goal in the prevention and treatment of T2DM.  
Hyperinsulinemia has been associated with inflammation (Pedersen et al., 2015; Pradhan, 
Cook, Buring, Manson, & Ridker, 2003; Yang, Gerber, & You, 2017) and numerous ill health 
effects including heart disease (Cabrera De León et al., 2015; Despres et al., 1996; Mitsuhashi et 
al., 2011) and stroke (Lindahl et al., 2000). However, the role of hyperinsulinemia in the 
development of inflammation is not well understood. Hyperinsulinemia likely plays a role in 
weight gain (Ebbeling et al., 2018; Ludwig & Ebbeling, 2018; Mehran et al., 2012), which has  
proinflammatory effects due to increasing visceral adipose tissue. However, proinflammatory 
effects have been observed independent of weight (Jansen et al., 2013; Pedersen et al., 2015). 
Understanding the relationship between insulin and inflammation may have important 
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implications for the treatment and prevention of T2DM, especially because many of the 
pharmaceutical treatments for T2DM increase insulin levels through endogenous or exogenous 
means (American Diabetes Association, 2020). Classes of medications that lower blood glucose 
but increase insulin levels and exacerbate hyperinsulinemia include exogenous insulin (insulin 
injections) and insulin secretagogues (sulfonylureas, meglitinides) (Crofts, Zinn, Wheldon, & 
Schofield, 2016). Other classes of medications including DPP-4s and GLP-1s, increase 
postprandial insulin levels (Chaudhury et al., 2017). However, GLP-1s exert other positive 
benefits including decreased glucagon, delayed gastric emptying, weight loss (Chaudhury et al., 
2017), and improved insulin sensitivity (Saraiva & Sposito, 2014), which may lower 
hyperinsulinemia in the long-term. Glucose-lowering medications that may decrease 
hyperinsulinemia include biguanides (e.g. metformin) which improve insulin sensitivity, inhibit 
gluconeogenesis (Chaudhury et al., 2017), and up-regulate glucose transporter type 4 (GLUT4) 
(Crofts et al., 2016). GLUT4 is one of a family of GLUT isoforms and it mediates the uptake of 
glucose in response to insulin (Karnieli & Armoni, 2008). Additionally, SGLT2s decrease 
insulin requirements and thus hyperinsulinemia by blocking 90% of glucose reabsorption in the 
kidneys (Ali et al., 2019; Chaudhury et al., 2017). Finally, while TZDs improve insulin 
sensitivity and don’t increase insulin levels, they do have other side effects that may negate this 
benefit (Crofts et al., 2016). 
High-sensitivity C-reactive protein (hs-CRP) is an acute-phase reactant produced in the 
liver and a sensitive marker of low-grade inflammation (Wang et al., 2013). Hs-CRP was 
associated with the markers of insulin resistance and fasting insulin among a nondiabetic 
population, and the relationship was attenuated after controlling for waist circumference (Meng 
et al., 2007). A positive association between fasting insulin and hs-CRP was also reported in a 
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population not taking glucose-lowering medications (Yang et al., 2017) and among nondiabetic 
females (Pradhan et al., 2003). The present study will extend these findings by utilizing differing 
methodology, a larger sample, and more recent cycles of NHANES data. Additionally, the 
relationship between insulin and inflammation has been evaluated in populations with T2DM 
and hyperglycemia (Khatana, Taveira, Dooley, & Wu, 2010). A direct association between CRP 
and both insulin use and dose were found in participants with a BMI of less than 30, but not in 
obese participants (Khatana et al., 2010). The proinflammatory features of hyperglycemia make 
it difficult to separate the effects of increasing insulin from its glucose-lowering effects in 
participants with T2DM. Additionally, insulin levels vary with T2DM duration and treatment, 
partly due to hyperglycemia, beta cell failure, and glucose-lowering medications. For these 
reasons it is difficult to discern the relationship between insulin and the inflammatory hs-CRP 
marker in a population with T2DM. It remains unclear how much this association between 
insulin and inflammation is mediated by visceral adipose tissue. More research is needed to 
identify the relationship between insulin and inflammation, and to begin to examine possible 
mediators.  
Objective 
The objective of the present study was to examine the independent association between 
fasting insulin and the inflammatory marker hs-CRP in individuals without diabetes. In addition, 
we examined the role of visceral adiposity in this relationship.   
Methods 
Data on hs-CRP, fasting insulin, obesity-related measurements and other characteristics 
were collected from the National Health and Nutrition Examination Survey (NHANES) 2005-
2010, conducted by the National Center for Health Statistics (NCHS) in the Centers for Disease 
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Control and Prevention. All the participants signed written consent, and the surveys were 
approved by the NCHS Institutional Review Board. Interviews and physical examinations were 
completed on a nationally representative sample of non-institutionalized individuals in the 
United States. A multi-stage sampling design with weighted domains was used to provide 
national estimates. Details of the sampling design and guidelines with the NHANES study have 
been described elsewhere (Zipf et al., 2013). 
Participants 
To address the issues related to insulin and glucose levels in participants with T2DM 
noted above, our sample included adults aged 20 years and older without a diagnosis of diabetes. 
While we did not exclude anyone based on an upper age limit, NHANES reports the age of all 
individuals aged 80 years and older as age 80. This allows them to ensure anonymity of 
participants due to fewer individuals in higher age groups. To reduce the bias in examining the 
independent associations between fasting insulin and hs-CRP, and make our analysis consistent 
with previous NHANES surveys, we excluded individuals younger than 20 years of age, those 
who have a self-reported diagnosis of diabetes, use glucose-lowering medications, use 
cholesterol-lowering medications (having an anti-inflammatory effect) (Bu, Griffin, & Lichtman, 
2011), or who were pregnant (due to changing physiology and waist circumference in 
pregnancy). The diabetes questionnaire provided information on the use of glucose-lowering 
medications or insulin injections. Individuals who self-reported use of these medications or 
treatments were excluded.  
Measures 
Hs-CRP. Detection of hs-CRP was done by latex-enhanced nephelometry, which 
allowed a conversion of the intensity of reflected light to milligrams of hs-CRP per deciliter 
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(mg/dL). Results were converted to mg/L to provide consistency with AHA risk categories. 
Chronic conditions such as arthritis and smoking may raise the levels of hs-CRP. 
Fasting insulin. Only subjects who fasted overnight and were tested in the morning 
session were included in the study. Insulin was detected in microunits per milliliter (µU/mL) 
with the ELISA technique, the technique used by NHANES since 2005.  
Waist circumference. Waist circumference was measured with a flexible measurement 
tape in centimeters by trained health technicians. The anatomical landmark was the lateral border 
of the right ilium. A cosmetic pencil was used to note this landmark just above its uppermost 
lateral border. 
Physical activity status. Physical activity status was established using the Global 
Physical Activity Questionnaire (GPAQ), (Centers for Disease Control and Prevention, 2011). 
This scale has been validated against accelerometer measurements. There was a moderate 
correlation between the self-reported questionnaires and accelerometer data with a wide 
interquartile range (Cleland et al., 2014). To reduce recurring small changes in surveys over the 
years, select survey questions/variables were dichotomized into subjects who participated in 
moderate or vigorous physical activity, or reporting no moderate or vigorous physical activity. 
These variables were then merged to create one dichotomous variable indicating whether the 
participant self-reported moderate or vigorous physical activity.  
Smoking status. Smoking status was dichotomized into current smoker or non-smoker. 
Former smokers were categorized as non-smokers. 
Demographic and socioeconomic factors. Age in years (analyzed as a continuous 
variable), race and ethnicity (non-Hispanic White/non-Hispanic Black/Other/Mexican or 
Hispanic), gender, and poverty-income ratio were obtained for each participant. Poverty-income 
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ratio is a measure used by NHANES to provide an index of the ratio of family income to 
poverty. NHANES reports any value greater than 5 as 5, and a higher index indicated higher 
income.  
Statistical Analyses 
Due to the need to utilize the fasting subsample weight (variable WTSAF2YR in 
NHANES) with the inclusion of insulin, we were unable to use the GLM model with a gamma 
distribution to account for the skewed nature of hs-CRP as originally planned. GLM models are 
very sensitive to sampling weights and resulted in a convergence error. Of note, other approaches 
of modeling the data were tried including log-transforming hs-CRP and using an ordinal model. 
Both were deemed inferior to Multinomial Logistic Regression in their ability to model the data.  
The American Heart Association recommends hs-CRP be used as an independent risk factor for 
cardiovascular disease, classified as low (< 1 mg/L), average (1 - 3 mg/L), and high (> 3 mg/L) 
risk (Pearson et al., 2003). Multinomial logistic regression, with hs-CRP categorized by the 
American Heart Association classification criteria was conducted to estimate the associations 
and p-values, which I hypothesized would be optimal in the low-risk group and increase 
incrementally in the average-risk and high-risk categories of hs-CRP. Average risk was used as 
the basis for comparisons. Summary characteristics of the sample will provide national estimates 
due to the complex sampling design. Number and proportion (expressed as percent) will be used 
to describe categorical variables while means and standard errors will be used to describe 
continuous variables with a normal distribution. Continuous variables with highly skewed 
variables will use the median and interquartile range to describe the distribution. Summary 
characteristics of the sample will also be analyzed based on the risk category of hs-CRP.  
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Two adjusted models were developed. The first or reduced model controlled for age, 
race, gender, smoking status, physical activity, and poverty-income ratio, but did not control for 
waist circumference. The second or full model controlled for waist circumference (as an 
indicator of visceral adipose tissue) and the covariates of the first model. These models tested my 
hypothesis that there was an independent association between fasting insulin and hs-CRP, and 
that visceral adipose tissue (as reflected in waist circumference) partially mediated this 
relationship. Therefore, controlling for waist circumference would reduce or attenuate the 
association between hs-CRP, a measure of inflammation, and fasting insulin. Margins is a post-
estimation option available in Stata to aid in understanding and interpreting regression results. 
This option was used to provide predicted proportions (displayed as a percent) for each 
categorical variable within high, average and low-risk hs-CRP categories. Unadjusted estimates 
were analyzed using multinomial logistic regression for each predictor variable and category of 
hs-CRP. Regressions will use males, non-Hispanic White race, non or former smoker, and no 
physical activity as the reference groups. Appropriate fasting sampling weights were used due to 
the complex sampling design to produce national estimates. All analyses were performed using 
Stata version 16, College Station, TX. 
Results 
 The demographic distribution of participants and their summary characteristics based on 
mean or median are presented in Table 1.1. The final sample included 4,527 adults with a mean 
age of 43.31 years, 49.03% of them male, 12.53% of Mexican or other Hispanic ethnicity, 
70.52% of non-Hispanic White, 10.73% of non-Hispanic Black, and 6.22% who identified as 
another race or multi-racial. Their mean BMI characterized them as overweight, and their fasting 
insulin was at the high end of normal relative to their normal blood glucose.  
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Table 1.2 presents means and proportions for summary characteristics of the sample 
stratified by the three categories of hs-CRP risk level. Table 1.3 provides the unadjusted 
multinomial logistic regression results showing the association between each variable and high 
or low-risk compared to average-risk hs-CRP.  
Table 1.4 presents the results of model one or the reduced model displaying the 
association between fasting insulin and hs-CRP adjusted for age, race, gender, smoking status, 
physical activity, and poverty-income ratio. Fasting insulin level was significantly associated 
with high-risk hs-CRP compared to average-risk hs-CRP (Relative risk ratio [RRR] 1.05, p < 
.001). Therefore, a one-unit increase in fasting insulin increased the relative risk of having a 
high-risk hs-CRP relative to average-risk hs-CRP, by a factor of 1.05. The second comparison 
from this regression compared low-risk hs-CRP to average-risk hs-CRP (RRR .91, p < .001). As 
fasting insulin increases in this contrast by one unit, the RRR for low-risk hs-CRP relative to 
average-risk hs-CRP would decrease by a factor of 0.91, if other covariates are held constant. 
Other covariates were also significant in this model. In this reduced model, comparing high-risk 
hs-CRP to average-risk hs-CRP, and comparing females to males, the expected difference in hs-
CRP was RRR 1.88, p < .001. This higher probability of having high-risk hs-CRP among 
females does not appear to be due to weight, as the mean BMI was lower among females (27.93 
kg/m2 , SE 0.18) compared to  males (28.09 kg/m2 , SE 0.17). When comparing low-risk hs-CRP 
to average-risk hs-CRP, and comparing females to males, the expected difference in hs-CRP was 
RRR .89, p = .178. The predicted probabilities for categorical variables are also provided in 
Table 1.4. 
Table 1.5 presents the results of model two, or the full model which controls for waist 
circumference and the other covariates analyzed in model one. In the full model, there was a 
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significant association (RRR of 1.01, p = .023) in comparison between high and average hs-CRP 
risk. Thus, after controlling for waist circumference, this association was attenuated (calculated 
by percent change in beta coefficients) by 68%. This indicates that some of the association 
observed between fasting insulin and hs-CRP was due to waist circumference (visceral adipose 
tissue). Therefore, visceral adipose tissue partially mediated the relationship between fasting 
insulin and hs-CRP. In addition, in the full model, a significant association was observed when 
comparing low-risk hs-CRP to average-risk hs-CRP (RRR 0.97, p < .001), which was attenuated 
by 69% between the full and the reduced model. Sex differences were also significant in this full 
model. Females had greater probability of high-risk hs-CRP than males (RRR 2.39, p < .001). 
This relationship was also significant when comparing low-risk to average-risk hs-CRP (RRR 
.62, p < .001). Table 1.6 also presents the predicted probabilities for this model. 
Discussion 
Since inflammation may significantly contribute to insulin resistance and development of 
T2DM, this study examined the association between fasting insulin and hs-CRP, a marker of 
inflammation. We conducted the analysis by comparing the levels of hs-CRP that are associated 
with high risk of cardiovascular disease (> 3 mg/L) with subjects presenting average-risk levels 
of hs-CRP (1 – 3 mg/L) as well as a comparison of subjects displaying low-risk levels of hs-CRP 
(< 1 mg/L) with those displaying average risk levels. We found a significant association between 
fasting insulin and high-risk hs-CRP in comparison to average-risk hs-CRP while controlling for 
age, race, gender, smoking status, physical activity, and poverty-income ratio in the reduced 
model, and while also controlling for waist circumference in the full model. The association 
between fasting insulin and high-risk hs-CRP was stronger in the reduced model and was 
attenuated by 68% between the reduced and full model. The present results confirm a previous 
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report of the association between insulin and hs-CRP while controlling for waist circumference 
(Meng et al., 2007). Both our and Meng et al. (2007) studies support the conclusion that this 
relationship between fasting insulin and inflammation is partially, but not entirely, mediated by 
waist circumference used here as a measure of visceral obesity. Additionally, there was a 
significant association between fasting insulin and low-risk hs-CRP compared to average-risk hs-
CRP in both the reduced and full models. This is in line with our hypothesis as it illustrates that 
those with higher levels of fasting insulin are less likely to have an hs-CRP in the low-risk 
category. Moreover, our results confirm the results of previous research that females are more 
likely to have elevated hs-CRP (Khera et al., 2005; Lakoski et al., 2006), a relationship that does 
not appear to be due to weight.  
The association between insulin and inflammation may have implications for treatment of 
those with T2DM. Current T2DM treatment guidelines recommend specific glycemic targets 
without consideration for the treatments’ effect on insulin. Many glucose-lowering medications 
increase insulin levels such as sulfonylureas and exogenous insulin, while other therapies 
decrease insulin requirements such as metformin (Kamenova, 2020) and SGLT-2s (Ali et al., 
2019).  Current medication guidelines recommend metformin as the first line of treatment 
(American Diabetes Association, 2020; Garber et al., 2020). Metformin controls blood sugar by 
decreasing hepatic gluconeogenesis and glucose secretion (Kamenova, 2020). It also decreases 
insulin resistance and hyperinsulinemia (Kamenova, 2020). Additionally, sodium-glucose 
cotransporter 2 inhibitors (SGLT-2) or glucagon-like peptide-1 receptor agonists (GLP-1s) are 
recommended for patients with established or at high risk for atherosclerotic cardiovascular 
disease (Garber et al., 2020).  
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Medications such as metformin (Triggle & Ding, 2014) and SGLT2s (Ali et al., 2019) 
have cardiovascular benefits that are not attributed to the decrease in HbA1c. Controlling HbA1c 
is more effective at preventing microvascular complications such as nephropathy and 
retinopathy, than macrovascular outcomes such as cardiovascular disease (Ali et al., 2019). 
Metformin and SGLT-2s improve many markers beyond HbA1c, including hyperinsulinemia 
(Ali et al., 2019; Triggle & Ding, 2014; UK Prospective Diabetes Study (UKPDS) Group, 1998). 
Additionally, GLP-1s improve insulin-sensitivity (Saraiva & Sposito, 2014) which may decrease 
hyperinsulinemia over time. GLP-1s exhibit anti-inflammatory effects, although the mechanism 
by which this occurs is still being investigated (Drucker, 2018). If higher insulin levels are 
associated with higher levels of inflammation, using therapies such as SGLT-2s and GLP-1s that 
simultaneously decrease insulin and glucose levels, should be recommended for all people with 
T2DM if additional pharmacotherapy is needed in addition to, or in place of, metformin. Based 
on the promising effects from medication trials, dietary strategies capable of simultaneously 
decreasing insulin and glucose levels may have similar positive cardiovascular benefits. 
GLP-1s and SGLT-2s may be prohibitively expensive for some individuals and are not 
available in a generic alternative. Dietary options capable of producing similar effects may be a 
more economically viable option for some. A study based on results from the National Health 
Interview Survey, found that almost 20% of adults with diabetes reported at least one cost barrier 
to receiving glucose-lowering medications (Knight, Probst, Liese, Sercye, & Jones, 2016). As 
carbohydrates are the primary driver of glucose excursions and the concordant increase in 
insulin, decreasing the carbohydrate load in the diet, may be one effective method. Although 
typical treatment goals for T2DM do not currently address inflammation (American Diabetes 
Association, 2020; Garber et al., 2020), decreasing inflammation may improve long-term 
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outcomes (Panee, 2012). Future studies are needed to evaluate the effect of different dietary 
approaches to decrease inflammation. 
Limitations of the present study include its cross-sectional nature and consequent 
inability to determine causality. Additionally, while there was a significant association, due to 
the small RRR and large sample size this relationship may not be clinically significant. The 
interplay between insulin and inflammation and between insulin, inflammation, and diabetes is 
complex and likely influenced by metabolic dysfunction, and therefore, the results of the present 
study may not generalize to a population of adults with T2DM. Despite this limitation, this study 
does provide insight into the association between fasting insulin and hs-CRP in adults without 
diabetes. Additional research is needed to increase our understanding of this relationship. 
This study found an association between fasting insulin and hs-CRP that was attenuated 
while controlling for waist circumference, demonstrating a partial contribution of this variable to 
this relationship. These results suggest that treatment approaches that simultaneously decrease 
insulin levels as well as glucose levels may provide additive anti-inflammatory effects, and 
therefore may improve long-term outcomes for adults with type 2 diabetes. 
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Table 1.1 
Demographic Distribution of Study Participants and Mean Summary Characteristics for 
Anthropometric and Glycemia Variables Among Adults without Diabetes 
Variable N=4527 
Categorical, N in millions (%)  
Sex  
     Male 75.43 (49.03) 
     Female 
 
78.39 (50.97) 
Race  
   White 108.48 (70.52) 
   Mexican/ Hispanic 
 
19.27 (12.53) 
   Black 
 
16.50 (10.73) 
   Other/Multi 
 
9.57 (6.22) 
Smoking  
    Non/former Smoker 
 
117.81 (76.59) 
    Current smoker  
 
36.01 (23.41) 
Physical Activity  
     No 37.59 (24.44) 
     Yes 116.23 (75.56) 
Continuous, mean (SE) or median (IQR) based on distribution 
Age years, mean (SE) 
 
43.31 (0.40) 
Poverty-Income Ratio, Mean (SE) 
 
3.06 (0.04) 
Waist Circumference cm, mean (SE) 
 
96.08 (0.38) 
Weight kg, mean (SE) 80.88 (0.38) 
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Body Mass Index kg/m2, mean (SE) 28.01 (0.13) 
Fasting glucose mg/dL, mean (SE) 98.79 (0.33) 
Hemoglobin A1c %, mean (SE) 5.35 (0.01) 
Fasting insulin µU/mL, median (IQR) 9.34 (6.00, 15.14) 
Hs-CRP mg/L, median (IQR) 1.5 (0.60, 4.00) 
Abbreviations: White – non-Hispanic White, Mexican/Hispanic – Mexican or other Hispanic ethnicity 
Black – non-Hispanic Black, other/multi – other race or Multiracial, SE-standard error 
Median and interquartile range (IQR) used for highly right skewed distributions 
Note: National estimates based on complex survey design  
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Table 1.2 
Means and Proportions for Summary Characteristics by Category of hs-CRP 
Variable 
 
 
 
 
Low Risk 
hs-CRP 
 < 1 mg/L2 
 
N=1574 
Average Risk 
hs-CRP  
1-3 mg/L 
 
N=1499 
High Risk 
hs-CRP  
> 3 mg/L 
 
N=1454 
Categorical, N in millions (%)   
Sex    
     Male 28.43 (37.70) 27.12 (35.96) 19.87 (26.34) 
     Female 25.04 (31.95) 23.82 (30.38) 29.53 (37.67) 
Race    
   White 
 
38.05 (34.77) 36.20 (33.10) 34.23 (32.13) 
   Mexican/ 
   Hispanic 
 
5.74 (29.05) 6.92 (36.44) 6.61 (34.50) 
   Black 
 
5.00 (37.82) 5.02 (31.36) 6.48 (30.82) 
   Other  
  /Multi 
 
4.68 (40.96) 2.80 (29.59) 2.09 (29.45) 
Smoking     
   Non/former 
    Smoker 
 
41.61 (35.32) 38.98 (33.09) 37.22 (31.60) 
    Current  
    Smoker  
 
11.87 (32.96) 11.96 (33.21) 12.18 (33.83) 
Physical Activity    
     No 9.80 (26.07) 12.11 (32.21) 15.68 (41.72) 
     Yes 43.68 (37.58)  38.83 (33.41) 33.72 (29.01) 
Continuous, Mean, (SE)    
Age, years 
 
40.39 (.56) 44.66 (.54) 45.08 (.46) 
Poverty-Income Ratio 
 
3.23 (0.06) 3.07 (0.06) 2.88 (0.06) 
Waist Circumference, cm 
 
87.58 (0.45) 96.45 (0.55) 104.90 (0.48) 
Weight, kg 
 
72.19 (0.48) 81.11 (0.65) 90.07 (0.58) 
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BMI, kg/m2 
 
24.62 (0.16) 27.89 (0.20) 31.82 (0.20) 
Fasting glucose, mg/dL 
 
96.10 (0.31) 98.37 (0.45) 102.14 (0.74) 
HbA1c% 
 
5.23 (0.01) 5.35 (0.01) 5.49 (0.02) 
Fasting insulin, µU/mL 
 
7.90 (0.19) 11.15 (0.31) 15.53 (0.35) 
Abbreviations: White – non-Hispanic White, Mexican/Hispanic – Mexican or other Hispanic ethnicity 
Black – non-Hispanic Black, other/multi – other race or Multiracial, SE – standard error 
Note: National estimates based on complex survey design 
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Table 1.3 
Unadjusted Associations Between Covariates and hs-CRP Category using Multinomial Logistic 
Regression 
Covariate Comparing Low-Risk to 
Average-Risk 
hs-CRP 
RRR (p-value1) 
 
Comparing High-risk to 
Average-Risk 
hs-CRP 
RRR (p-value2) 
Age 0.98 (<.001) * 1.00 (.503) 
Sex   
     Male 1.0 (Reference) 1.0 (Reference) 
     Female 1.00 (.971) 1.69 (<.001) * 
Race   
     White 1.0 (Reference) 1.0 (Reference) 
      Mexican/Hispanic 0.79 (.041) * 1.01 (.918) 
     Black 0.95 (.622) 1.36 (.005) * 
     Other/Multi 1.59 (.015) * 0.79 (.336)  
Poverty-income Ratio 1.06 (.023) * 0.93 (.003) * 
Smoking   
     Non-smoker 1.0 (Reference) 1.0 (Reference) 
     Current smoker .93 (.468) 1.07 (.437) 
Physical Activity   
     No 1.0 (Reference) 1.0 (Reference) 
     Yes 1.39 (.004) * .67 (<.001) 
Abbreviations: White - Non-Hispanic White, Mexican/Hispanic – Mexican or other Hispanic ethnicity, 
Black – non-Hispanic Black, Other/Multi – other race or Multiracial,  
1P-value calculated with bivariate multinomial logistic regression comparing low-risk hs-CRP (<1) to 
average-risk (1-3) hs-CRP with each independent variable separately. Reference is the reference group 
used in the regression, so p-value not provided 
2P-value calculated with bivariate multinomial logistic regression comparing high-risk hs-CRP (>3) to 
average-risk (1-3) hs-CRP with each independent variable separately. Reference is the reference group 
used in the regression, so p-value not provided 
*Significant at p-value of .05 
Note: National estimates based on complex survey design 
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Table 1.4.  
Model one or Reduced Model: Adjusted Association Between Fasting Insulin and hs-CRP 
Category Among Adults Without Diabetes 
Independent 
Variable 
Low Risk  
hs-CRP 
 < 1 mg/L 
RRR (p-value) 
High Risk  
hs-CRP 
 >3 mg/L 
RRR (p-value) 
Low-Risk 
hs-CRP 
< 1 mg/L1 
Predicted 
Probability  
 
Average-Risk 
hs-CRP 
1-3 mg/L1 
Predicted 
Probability  
 
High-Risk 
hs-CRP 
>3 mg/L1 
Predicted 
Probability 
 
Age 0.98 (<.001) * 1.00 (.297)     
Sex      
     Male 1.0 (Reference) 1.0 (Reference)  35.14 36.83 28.03 
     Female .89 (.178)  1.88 (<.001) * 29.55 30.62 39.83 
Race      
     White 
       
1.0 (Reference)  1.0 (Reference)  32.36 33.94 33.70 
     Mexican/ 
     Hispanic 
 
0.83 (.150)  0.91 (.419) 27.98 35.99 36.03 
     Black 
                      
1.03 (.793) 1.18 (.131) 28.14 30.69 41.17 
     Other/ 
     Multi 
 
1.54 (.021)* 0.73 (.230)  46.39 30.45 23.16 
Poverty-Income 
Ratio 
 
1.04 (.162) 0.98 (.311)     
Smoking Status      
     Non-smoker 1.0 (Reference)  1.0 (Reference)  32.61 33.68 33.72 
     Current Smoker 0.74 (.006)* 1.22 (.029) * 30.95 33.39 35.66 
Physical Activity      
     No                    1.0 (Reference)  1.0 (Reference)  23.51 32.48 44.00 
     Yes 1.09 (.413) 0.78 (.027) * 35.59 34.05 30.36 
Fasting Insulin, 
µU/mL 
0.91 (<.001) * 1.05 (<.001) *    
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Abbreviations: White - Non-Hispanic White, Mexican/Hispanic – Mexican or other Hispanic ethnicity, , 
Black – non-Hispanic Black, Other/Multi – other race or Multiracial; hs-CRP, high-sensitivity C-reactive 
protein, RRR, relative risk ratio.  
Reduced Model: controlling for age, sex, race, socioeconomic status (poverty-income ratio), smoking 
status, physical activity, and fasting insulin 
Multinomial logistic regression used in estimations, reference group is the reference group used for each 
categorical variable 
1Probabilities calculated from margins command for categorical variables. 
* indicated that the difference was significant at the .05 level. 
Note: National estimates based on complex survey design 
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Table 1.5 
  
Model 2 or Full Model: Adjusted Association Between Fasting Insulin and hs-CRP Category 
Among Adults Without Diabetes 
Independent 
Variable 
Low Risk  
hs-CRP 
 < 1 mg/L 
RRR(p-value) 
High Risk  
hs-CRP 
 >3 mg/L 
RRR(p-value) 
Low-Risk  
hs-CRP 
< 1 mg/L1 
Predicted 
Probability 
 
Average Risk 
hs-CRP 
1-3 mg/L1 
Predicted 
Probability  
 
High-Risk 
hs-CRP 
>3 mg/L1 
Predicted 
Probability 
 
Age 0.99 (<.001)* 1.00 (.646)   . 
Sex      
     Male 1.0 (Reference) 1.0 (Reference) 34.54 36.68 28.78 
     Female 0.62 (<.001) 2.39 (<.001)* 28.80 30.43 40.77 
Race      
     White 1.0 (Reference) 1.0 (Reference) 31.67 33.79 34.55 
     Mexican/ 
     Hispanic 
0.81 (.109) 1.02 (.851) 27.79 35.88 36.34 
     Black .98 (.833) 1.18 (.130) 27.12 30.29 42.59 
     Other/ 
     Multi 
1.24 (.291) 0.86 (.564) 45.67 30.47 23.86 
Poverty-Income 
Ratio 
1.05 (.068) 0.97 (.328)    
Smoking Status      
     Non-smoker 1.0 (Reference) 1.0 (Reference) 31.97 33.55 34.48 
     Current Smoker 0.68 (.002) 1.32 (.004)* 30.17 33.13 36.70 
Physical Activity      
     No 1.0 (Reference) 1.0 (Reference) 22.60 32.03 45.37 
     Yes 1.10 (.379) 0.82 (.067) 34.92 33.99 31.09 
Waist 
Circumference, cm 
0.95 (<.001)* 1.04 (<.001)*    
Fasting Insulin, 
µU/mL 
.97 (<.001)* 1.01 (.023)*    
Abbreviations: White – non-Hispanic White, Mexican/Hispanic – Mexican or other Hispanic ethnicity, 
Black – Non-Hispanic Black, Other/Multi – other race or Multiracial; hs-CRP, high-sensitivity C-reactive 
protein; RRR, relative risk ratio.  
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Full Model: controlling for age, sex, race, socioeconomic status (poverty-income ratio), smoking status, 
physical activity, waist circumference and fasting insulin 
Multinomial logistic regression used in estimations, reference group is the reference group used 
for each categorical variable 
1Probabilities calculated from margins command for categorical variables. 
* indicated that the difference was significant at the .05 level. 
Note: National estimates based on complex survey design 
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Chapter Four 
Association Between Net Carbohydrate and Sugar Intake on Inflammation and 
Hemoglobin A1c in Adults with Diabetes 
Type 2 diabetes (T2DM) is a highly prevalent chronic condition which affects 
approximately 34 million Americans (U.S. Department of Health and Human Services, 2020). 
Many adults fail to meet treatment goals. The American Diabetes Association recommends a 
hemoglobin A1c (HbA1c) goal of less than 7% (American Diabetes Association, 2020). 
However, CDC data from 2013-2016 reveal that 50% of people diagnosed with diabetes have an 
HbA1c above the goal of 7%, and 14.6% had an HbA1c above 9% (U.S. Department of Health 
and Human Services, 2020). Diabetes places individuals at risk for developing many long-term 
complications, including cardiovascular disease, retinopathy, nephropathy and neuropathy. 
Hyperglycemia increases this risk (U.S. Department of Health and Human Services, 2020). 
Inflammation, although not a current treatment target, is also involved in the development of 
long-term complications related to diabetes (Donath, 2014; Panee, 2012). Therefore, identifying 
strategies that simultaneously decrease hyperglycemia as well as inflammation may improve 
outcomes and the risk of long-term complications in this population.  
Dietary strategies may be one way to accomplish this goal. The average adult in the 
United States consumes 17.6 teaspoons (74 grams) of sugar per day (Bowman et al., 2017). This 
is well above the recommended limit from the American Heart Association (25 grams of added 
sugar for females and 36 grams for males per day) (Johnson et al., 2009). The daily sugar intake 
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limit proposed by the World Health Organization is 10% of calories from free sugar (World 
Health Organization, 2015). For someone consuming 2,000 calories per day, that would equate 
to 50 grams of sugar. High sugar intake is associated with diabetes (Malik & Hu, 2015) and heart 
disease (Yang et al., 2014), likely due, in part, because carbohydrates are the primary 
macronutrient responsible for postprandial glucose excursions (Evert et al., 2019). Moreover, 
meals that promote a rapid postprandial rise in glucose generate free radicals resulting in 
inflammation (O'Keefe, Gheewala, & O'Keefe, 2008), and indeed, fructose or dietary sugar 
(combination of glucose and fructose) (Aeberli et al., 2011; DiNicolantonio, Mehta, 
Onkaramurthy, & O'Keefe, 2018), and higher levels of refined carbohydrates in general (O'Keefe 
et al., 2008) promote inflammation. Current treatment guidelines do not address decreasing 
chronic inflammation as a goal in the treatment of T2DM (American Diabetes Association, 
2020). However, it may be possible to improve outcomes in the treatment of T2DM by 
examining the impact of carbohydrate intake, irrespective of diet type, on glycemic control and 
inflammation. Therefore, to address this knowledge gap, it will be useful to increase our 
understanding of the relationship between sugar and net carbohydrate intake (total carbohydrates 
– fiber) and their effect on hyperglycemia and inflammation in a population with diabetes. 
Increasing our understanding of these effects may provide insight into the best dietary options to 
treat T2DM. The purpose of this study is to examine the association between sugar and net 
carbohydrate content in the diet, on inflammation and HbA1c.  
Methods 
The present study focused on an adult population with diabetes, to discern the association 
between diet (sugar and net carbohydrate content intake), on inflammation and HbA1c, using 
National Health and Examination Survey (NHANES) data. NHANES is conducted by the 
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National Center for Health Statistics in the Centers for Disease Control and Prevention and 
includes a series of two-year cross-sectional surveys to assess health and nutrition status among 
non-institutionalized residents of the United States. NHANES used a multi-stage sampling 
design with weighted domains, to provide national estimates. Details of this study have been 
described elsewhere (Chen, Clark, Riddles, Mohadjer, & Fakhouri, 2020; U.S. Department of 
Health and Human Services, 2014). Inclusion criteria were adults aged 20 years of age and older 
with diabetes. A diagnosis of diabetes was determined by a questionnaire, which asked, “doctor 
told you have diabetes” or “borderline diabetes” and/or an HbA1c of 6.5 or higher. We used 
white blood cell count (WBC) at the higher end of the normal range as a marker of inflammation 
in the 2011-2016 NHANES data. WBC at the higher end of the normal range is used to 
distinguish its function as a marker of inflammation from its supranormal elevations for 
numerous reasons including active infections. Exclusion criteria included current pregnancy and 
predictor variables above the 99th percentile. There were substantial outliers for predictor 
variables including carbohydrate and sugar intake. As our goal was to make inferences about the 
average adult in the United States, we excluded these outliers so that they do not create undue 
influence in the analysis. Inflammation and hyperglycemia can be modified by multiple factors. 
Two separate adjusted models were used to examine effects on WBC. The first examined the 
association between net carbohydrates and WBC, and the second, the association between total 
sugar and WBC. Both adjusted models also controlled for age, sex, race/ethnicity, poverty-
income ratio (measure of socioeconomic status), smoking status, physical activity, use of 
cholesterol medication and waist circumference. Additionally, two adjusted models assessed the 
effect on HbA1c. The first examined the association between net carbohydrate and HbA1c, and 
the second examined the association between total sugar intake and HbA1c. Both models 
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controlled for age, sex, race/ethnicity, poverty-income ratio, smoking status, physical activity, 
and waist circumference.  
Outcome Measures 
Marker of inflammation: White blood cell count (WBC). We measured WBC count as 
a component of the complete blood cell count because at the higher end of the normal range, it is 
a useful indicator of inflammation and is associated with both macro and microvascular 
complications in people with T2DM (Tong et al., 2004). The specimen was collected using an 
EDTA blood tube and run on a Coulter DxH 800 (hematological analyzer that provides a full 
hematological profile which includes a count of WBC). Results were reported in 1000 cells per 
microliter (1000 cells/µL). 
Glycohemoglobin/Hemoglobin A1c (HbA1c). Results, reported as a percent, provide 
the average blood glucose over the previous 120 days.  
Covariate Measures 
Demographics. Age, race, sex, and poverty-income ratio were obtained for each 
participant. Poverty-income ratio is an NHANES index of the ratio of family income to poverty,  
with 5 representing ratios of 5 and above. Additionally, anyone aged 80 years of age or older had 
their age reported as 80. Therefore, age and poverty-income ratio were not trimmed further to the 
99th percentile. 
Waist circumference. Waist circumference was measured in centimeters with a flexible 
tape measure by trained health technicians. The anatomical landmark was the lateral border of 
the right ilium and was marked with a cosmetic pencil just above the uppermost lateral border.  
Because visceral adipose tissue increases inflammation (Makki, Froguel, & Wolowczuk, 2013), 
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and overweight and obesity impact glucose levels (American Diabetes Association, 2020), waist 
circumference was included as a covariate in all models (effect on WBC and effect on HbA1c). 
Physical activity status. Since exercise lowers WBC (Loprinzi & Ramulu, 2013), and 
glucose levels (Church et al., 2010), physical activity was assessed with the Global Physical 
Activity Questionnaire (GPAQ) (Centers for Disease Control and Prevention, 2017). This 
questionnaire was validated against accelerometer measurements (Cleland et al., 2014), and the 
two measurements were moderately correlated (Cleland et al., 2014). Select survey 
questions/variables were dichotomized into one of the following: (a) participates in moderate or 
vigorous physical activity, or (b) no report of moderate or vigorous physical activity to reduce 
recurrent small changes in the activity questionnaire. These variables were then merged to create 
one dichotomous variable indicating whether participants self-reported moderate or vigorous 
physical activity. Exercise was included as a covariate in all models (effect on WBC and effect 
on HbA1c). 
Smoking status. As it raises WBC (Higuchi et al., 2016) and glucose levels (Clair, 
Bitton, Meigs, & Rigotti, 2011), smoking was included as a covariate in all models. Smoking 
status was dichotomized into current smoker or non-smoker with former smokers categorized as 
non-smokers.  
Carbohydrate intake. Twenty-four-hour dietary recalls were assessed in all individuals. 
This component of the interview is called “What We Eat in America (WWEIA)” (Centers for 
Disease Control and Prevention, 2018). The data were collected using the Automated Multiple 
Pass Method (AMP), which were validated for assessments of energy intake in adults (Centers 
for Disease Control and Prevention, 2018). Two interviews were conducted, once during the 
physical examination, and a second interview by phone. This information was provided in raw 
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and aggregate form based on participant interviews. Aggregate data included total carbohydrates, 
total fiber, and total sugar in grams. This study used total mass of dietary carbohydrate and 
dietary fiber to calculate net carbohydrate intake (total grams of carbohydrate – fiber). A two-day 
average was calculated when data were available.  
Use of cholesterol-lowering medication. As statin medications also work by decreasing 
inflammation (Bu, Griffin, & Lichtman, 2011), this was used as a covariate in the two models 
examining the effect on WBC. 
Statistical Analysis 
Multiple linear regression was used to analyze the effect of sugar and net carbohydrate on 
WBC. Waist circumference and net carbohydrate intake were split into quintiles, to analyze 
potential non-linear relationships. Stata provides a margins option from predictions made from a 
regression model. Predictive margins are one option available to provide additional detail on 
relationships in a model including p-values and 95% confidence intervals, that may aid in 
understanding and interpreting a model. This option was used to predict the WBC value after 
adjusting for the interaction between quintile of waist circumference and quintile of net 
carbohydrate as a whole, for males and females separately. To analyze the effect of diet on 
HbA1c, which has a highly right-skewed distribution, generalized linear models with gamma 
distribution and identity link function were conducted to estimate the associations. Regressions 
used males, non-smokers, no physical activity, and not taking cholesterol medications as the 
reference groups for categorical variables. The appropriate sampling weights were used during 
the analyses as required when complex sampling designs are used to produce national estimates. 
All analyses were performed using Stata version 16, College Station, TX. 
Results 
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 Table 2.1 provides the demographic distribution of study participants and mean summary 
characteristics for key study variables. The final sample included 1,709 participants and was 
used to produce national estimates. The mean age of the sample was 59.53 years, of which 
50.26% were male, 14.63% were Mexican or another Hispanic ethnicity, 63.15% were non-
Hispanic White, 13.61% were non-Hispanic Black, 5.11% were Asian, and 3.5% were of another 
race or identified as more than one race.  
Dietary macronutrient intake by sex are presented in Table 2.2. Additionally, the mean 
caloric intake at the lowest carbohydrate quintile was 1,088 kcal, while the highest quintile was 
2,855 kcal. In the lowest quintile of carbohydrate intake, the mean fat intake was 44.6 grams, or 
37% of calories from fat. Additionally, mean caloric intake was 1,871 kcal for those who 
reported following a diet compared to 1,968 kcal for those who did not. The proportion of net 
carbohydrate and sugar intake as a function of total energy intake was similar in the two sexes. 
Unadjusted and adjusted estimates between net carbohydrate intake and WBC are 
reported in Table 2.3. Unadjusted bivariate estimates found that age (β = -0.009, p = .006), 
female sex (β = 0.181, p = .026), non-Hispanic Black race (β = -0.525, p < .001), Asian race (β =  
-0.341, p = .029), Multiracial or another race (β = -0.700, p = .007), current smoker (β = 0.565, p 
< .001), waist circumference (β = 0.017, p < .001), and net carbohydrates (β = 0.001, p = .035), 
were all correlated with higher WBC. While the unadjusted bivariate association between net 
carbohydrate intake and WBC was β =  0.001, p = 0.035, after adjusting for age, sex, race, 
poverty-income ratio, smoking status, physical activity, taking cholesterol medications, and waist 
circumference, the association between net carbohydrate intake and WBC was β = 0.001 and p = 
.047. In the adjusted model, female sex (β = 0.267, p = .001), Non-Hispanic Black race (β = -
 
 
  90 
 
0.637, p < .001), Multiracial or other race (β = -0.889, p = .001), current smoker (β = 0.622, p < 
.001), and waist circumference (β = 0.019, p < .001) were also significant. 
The predicted margins were examined using quintiles for waist circumference and net 
carbohydrate intake for all individuals, and for men and women separately. The interaction 
between quintile of waist circumference and quintile of net carbohydrate intake on WBC is 
depicted for all adults in Figure 2.1, for males only in Figure 2.2, and for females only in Figure 
2.3. The lowest quintile of net carbohydrate intake had a mean of 102 grams of net carbohydrate 
intake per day, while the highest quintile had a mean of 333 grams per day. The lowest quintile 
of waist circumference had a mean of 88 cm, while the highest was 129 cm. For all individuals, 
at the highest waist circumference, the lowest quintile of net carbohydrate intake resulted in the 
lowest mean WBC (mean WBC 7.46, 95% CI 6.97, 7.94). This was significantly different (0.72, 
p = .023) than the 4th highest quintile of net carbohydrate intake that resulted in the highest mean 
WBC (8.18, 95% CI 7.78, 8.58). In men, at the highest quintile of waist circumference, the 2nd 
quintile of net carbohydrate (mean 151 grams) resulted in the lowest mean WBC (7.40, 95% CI 
6.97, 7.83). When the relationship was analyzed among females at the highest quintile of waist 
circumference, the relationship was more complex. The highest quintile with a mean net 
carbohydrate intake of 335 grams (mean WBC 7.60, 95% CI 6.92, 8.27) and lowest quintile with 
a mean net carbohydrate intake of 99 grams (mean WBC 7.39, 95% CI 6.80, 7.97) resulted in the 
lowest WBCs.  
Adjusted estimates between total sugar and WBC are reported in Table 2.4 (unadjusted 
are repeated for comparison purposes). After adjusting for age, sex, race, poverty-income ratio, 
smoking status, physical activity, taking cholesterol medications, and waist circumference (same 
confounders as effect of net carbohydrate on WBC) there was no association between total sugar 
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intake and WBC (β = 0.000, p = .838). In this model, female sex (β = .232, p = .004), non-
Hispanic Black race (β = -0.646, p < .001), Multiracial or other race (β = -0.878, p = .002), 
current smoker (β 0.639, p <.001), and waist circumference (β = 0.019, p < .001) were 
statistically significant..  
The results which include unadjusted and adjusted estimates analyzing the association 
between net carbohydrate intake and HbA1c are reported in Table 2.5. The unadjusted and 
adjusted association between total sugar and HbA1c are reported in Table 2.6. After adjusting for 
confounders, neither total net carbohydrates (β = 0.001, p = .311) nor total sugar (β = -0.000, p = 
.815), were associated with HbA1c. While examining the adjusted association between net 
carbohydrate and HbA1c, age (β -0.010, p=.038), female sex (β = -0.246, p =.016), Mexican or 
other Hispanic ethnicity (β = 0.696, p < .001), Non-Hispanic Black race (β = 0.522, p < .001), 
Asian race (β = 0.366, p = .007), physical activity (β = -0.304, p =.016), and waist circumference 
(β = 0.016, p < .001) were all significant. When examining the adjusted association between total 
sugar and HbA1c, age (β = -0.011, p = .022), female sex (β = -0.275, p = .007), Mexican or other 
Hispanic ethnicity (β = 0.685, p < .001), non-Hispanic Black race (β = 0.515, p < .001), Asian 
race (β = 0.349, p = .010), physical activity (β = -0.298, p = .018), and waist circumference (β = 
0.016, p < .001) were all significant. Examining the association between covariates and HbA1c 
found that age (β = -.014, p = .003), female sex (β = -.272, p = .012), Hispanic ethnicity (β = 
.694, p < .001), non-Hispanic Black race (β = .545, p < .001), physical activity (β = -.309, p = 
.025), and waist circumference (β = .017, p = .001) were significant.  
Discussion 
 This study tested the hypothesis that total net carbohydrate and sugar intake by adults 
with T2DM are associated with inflammation as measured by the upper normal range of WBC 
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counts and HbA1c. After adjusting for confounders, we found a moderate but significant 
association between net carbohydrate intake and WBC (β = 0.001, p = .047). However, after 
adjusting for confounders, no association was found between total sugar intake and WBC, 
between net carbohydrate intake and HbA1c, or between total sugar intake and HbA1c. 
The significance of this study is in its scope. It reveals the association between net 
carbohydrate load and sugar on WBC and HbA1c in a nationally representative sample of adults 
with diabetes. Although the cross-sectional design of this study is not capable of proving 
causality, it does suggest that lower net carbohydrate intake may reduce chronic inflammation. 
This study suggests that subjects with diabetes have some difficulty processing larger 
carbohydrate loads. The physiologic basis of this inference is due to higher levels of insulin 
resistance, which is suggested by their higher waist circumference (Stepien et al., 2011).  
The mean caloric intake at the lowest carbohydrate quintile was 1,088 kcal and 2,855 
kcal at the highest quintile. As lower calorie diets have also been associated with lower levels of 
inflammation (Gonzalez, Tobia, Ebersole, & Novak, 2012), this may also be responsible for the 
observed effect. Total fat and saturated fat were also higher at higher quintiles of carbohydrate 
intake, indicating those at the highest levels of carbohydrate intake, were also following a high 
fat diet. The combination of a high-calorie, high-fat, high-carbohydrate diet likely led to the 
higher levels of inflammation. However, it is important to note that advocates of a lower 
carbohydrate diet for those with T2DM do not necessarily recommend increasing fat or protein 
in the diet (Volek & Phinney, 2011). It is recommended to eat a moderate amount of protein and 
fat until satiation (Volek & Phinney, 2011). Individuals trying to lose weight, would obtain a 
greater percentage of their energy needs from mobilized body fat, not fat consumption. In the 
present sample, individuals with the lowest quintile of carbohydrate intake, had an average fat 
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intake of 37% of calories, which is above what is recommended under typical low-fat diets 
containing < 30% calories as fat (Tobias et al., 2015). The total number of grams of fat is still 
substantially lower than those following the high-carbohydrate, high fat diet (44.60 grams versus 
109.61 grams of fat). This suggests that increased percentage of calories from fat on lower-
carbohydrate diets do not lead to substantially greater intake of calories. Additionally, caloric 
intake was 1,871 kcal for those who reported following a dietary restriction compared to 1,968 
kcal for those who did not. Highly refined carbohydrates may increase feelings of hunger and 
decrease the length of satiation (Chandler-Laney et al., 2014; Pan & Hu, 2011; Spadaro, Naug, 
EF, Donner, & Colson, 2015). While it is not possible to examine satiation in this sample, it is 
one possible explanation for lower caloric intake observed in those following a lower 
carbohydrate diet.  
Lower carbohydrate diets may decrease inflammation (Al-Sarraj, Saadi, Calle, Volek, & 
Fernandez, 2009; Athinarayanan et al., 2019; Forsythe et al., 2008; Hu et al., 2013; Jonasson, 
Guldbrand, Lundberg, & Nystrom, 2014; Seshadri et al., 2004). While many randomized trial 
results were limited by small sample size and short duration (Al-Sarraj et al., 2009; Forsythe et 
al., 2008; Seshadri et al., 2004), positive anti-inflammatory effects were observed at two years in 
one trial using a very low-carbohydrate diet (Athinarayanan et al., 2019). Therefore, there is still 
a lack of consensus about the best diet to follow with a diagnosis of T2DM. Large randomized 
controlled trials of longer duration are needed to understand the nuances of different diet types.  
 This study has several limitations. First, its cross-sectional nature precludes the ability to 
determine cause and effect. Based on these results, we were unable to determine definitively 
whether there is a causal relationship between diet and changes in inflammation or HbA1c. 
Second, this is a secondary analysis, in which the participants may have additional diagnoses and 
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confounding factors that we are unable to control for. Third, this study was limited due to the use 
of aggregate dietary data. Therefore, we were unable to distinguish between added sugar and 
naturally occurring sugar, and between whole grains versus highly refined carbohydrates. 
Additionally, the mean number of carbohydrates was 102 grams in the lowest carbohydrate 
intake quintile, therefore we are unable to make inferences on very low-carbohydrate diets. 
Furthermore, dietary data was collected via self-report, which may have led to underreporting. 
Finally, the effect observed between net carbohydrates and WBC was small with a relatively 
large sample, and therefore the results may not be clinically significant. 
The American Diabetes Association does not recommend one specific diet for subjects 
with diabetes, nor do they set specific recommendations for carbohydrate intake (American 
Diabetes Association, 2020). Furthermore, the guidelines for diabetes treatment do not include 
inflammation (American Diabetes Association, 2020). Identifying dietary strategies capable of 
simultaneously decreasing glucose levels and inflammation may improve the outcomes and 
decrease long-term complications for those diagnosed with T2DM. Additional research is needed 
to improve our understanding on the effects of dietary choices on inflammation, and possible 
benefits of such diets to individuals with T2DM. However, the results of this trial suggest that 
lower levels of carbohydrate intake may be beneficial for individuals with T2DM.  
In this study, we found a significant association between net carbohydrate intake and 
WBC concentration at the higher range of normal, which reflects inflammation (β = 0.001, p= 
.035). This relationship persisted after adjusting for confounders (β = 0.001, p = .047). As 
carbohydrates are the predominant macronutrient responsible for glucose excursions (Evert et al., 
2019b), reducing carbohydrate load may improve glycemic control while simultaneously 
decreasing inflammation. 
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Table 2.1 
 
Demographic Distribution of Study Participants and Mean Summary Characteristics of Key 
Variables for Adults with Diabetes  
Variable All 
Sample size, N (unweighted) 1,709 
Sample size (weighted) 
 
311,425,314 
Categorical, N in millions (%) 
 
 
Sex, % 
 
 
     Male 
 
9.85 (50.26) 
     Female 
 
9.75 (49.74) 
Race, % 
 
 
     Mexican/Hispanic 
 
2.87 (14.63) 
     White 
 
12.38 (63.15) 
     Black 
 
2.67 (13.61) 
     Asian 
 
1.00 (5.11) 
     Other/Multi 0.69 (3.50) 
Smoking 
 
 
     Non-smoker 
 
16.73 (85.35) 
     Current smoker 2.87 (14.65) 
Physical Activity 
 
 
     No 
 
7.51 (38.3) 
     Yes 12.10 (61.7) 
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Glucose-Lowering Medications 
 
 
     Taking Oral 
 
11.23 (61.71) 
     Taking Insulin 
 
3.74 (19.12) 
Continuous, mean (SE) 
 
 
Age, years 
 
59.53 (0.44) 
Poverty-Income Ratio 
 
2.80 (0.06) 
Waist Circumference, cm 109.02 (0.53) 
BMI kg/m2 31.68 (0.24) 
Fasting insulin, µU/mL 
 
17.96 (0.52) 
Fasting glucose, mg/dL 151.45 (2.38) 
HbA1c % 
 
7.14 (0.06) 
Number of years diagnosed with diabetes  8.32 (1.12) 
Total sugar, grams 91.10 (1.58) 
Net Carbohydrates, grams 207.93 (2.60) 
Abbreviations: White – non-Hispanic White, Mexican/Hispanic – Mexican or other Hispanic ethnicity, 
Black – Non-Hispanic Black, Other/Multi – other race or Multiracial SE – standard error, BMI – body 
mass index 
National estimates based on complex sampling survey design.  
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Table 2.2 
Summary Characteristics of Diet and Weight by Sex 
Diet Males, mean (SE) Females, mean (SE) 
Total Calories, kcal  
 
2187.54 (32.54) 1680.27 (29.26) 
Net Carbohydrates, grams  
 
228.48 (3.62) 187.16 (3.62) 
Total Sugar, grams  
 
97.55 (2.50) 84.58 (1.95) 
Total Protein, grams  
 
89.43 (1.41) 66.45 (1.13) 
Total Fat, grams  
 
88.04 (1.68) 67.89 (1.48) 
Weight, kg 
 
94.50 (1.04) 84.06 (0.99) 
Abbreviations: SE-standard error 
National estimates based on complex survey design 
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Table 2.3 
Unadjusted and Adjusted Estimates of the Association Between Net Carbohydrate Intake and 
White Blood Cell Count 
Independent Variable Unadjusted 
β (p-value) 
Adjusted 
β (p-value) 
Age 
 
-0.009 (.006) * -0.005 (.146) 
Sex 
 
  
     Male 
 
0.0 (Reference) 0.0 (Reference) 
     Female 
 
0.181 (.026) * 0.267 (.001) * 
Race 
 
  
     White 
 
0.0 (Reference) 0.0 (Reference) 
     Mexican/ Hispanic 
 
0.019 (.87) 0.016 (.896) 
     Black 
 
-0.525 (<.001) * -0.637(<.001) * 
     Asian 
 
-0.341 (.029) * 0.003 (.983) 
     Other/Multi 
 
-0.700 (.007) * -0.889 (.001) * 
Poverty-Income Ratio 
 
-0.059 (.065) -0.049 (.086) 
Smoking 
 
  
     Non-Smoker 
 
0.0 (Reference) 0.0 (Reference) 
     Current smoker 
 
0.565 (<.001) * 0.622 (<.001) * 
Physical Activity   
     No 
 
0.0 (Reference) 0.0 (Reference) 
     Yes 
 
-0.083 (.378) 0.002 (.982) 
Taking Cholesterol Medication 
 
  
     No 
 
0.0 (Reference) 0.0 (Reference) 
     Yes 
 
-0.063 (.563) -0.067 (.554) 
Waist Circumference, cm 0.017 (<.001) * 0.019 (<.001) * 
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Total Net Carbohydrates, grams 0.001 (.035) * 0.001 (.047) * 
Abbreviations: White – non-Hispanic White, Mexican/Hispanic – Mexican or other Hispanic ethnicity, 
Black – Non-Hispanic Black, Other/Multi – other race or Multiracial WBC – white blood cell count, 
 * significant at .05 
Unadjusted estimates from bivariate regression 
Adjusted estimates controlled for age, sex, race, poverty-income ratio, smoking status, physical activity, 
use of cholesterol medication and waist circumference 
National estimates based on complex survey design  
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Table 2.4 
 
Unadjusted and Adjusted Estimates on the Association Between Total Sugar Intake and White 
Blood Cell Count 
Independent Variable Unadjusted 
β (p-value) 
Adjusted 
β (p-value) 
Age 
 
-0.009 (.006) * -0.006 (.086) 
Sex 
 
  
     Male 
 
0.0 (Reference) 0.0 (Reference) 
     Female 
 
0.181 (.026) * 0.232 (.004) * 
Race 
 
  
     White 
 
0.0 (Reference) 0.0 (Reference) 
     Mexican/ Hispanic 
 
0.019 (.87) 0.011 (.929) 
     Black 
 
-0.525  (<.001) * -0.646 (<.001) * 
     Asian 
 
-0.341 (.029) * -0.005 (.976) 
     Other/Multi 
 
-0.700 (.007) * -0.878 (.002) * 
Poverty-Income Ratio 
 
-0.059 (.065) -0.048 (.090) 
Smoking 
 
  
     Non-Smoker 
 
0.0 (Reference) 0.0 (Reference) 
     Current smoker 
 
0.565 (<.001) * 0.639 (<.001) * 
Physical Activity   
     No 
 
0.0 (Reference) 0.0 (Reference) 
     Yes 
 
-0.083 (.378) -0.005 (.959) 
Taking Cholesterol Medication 
 
  
     No 
 
0.0 (Reference) 0.0 (Reference) 
     Yes 
 
-0.063 (.563) -0.070 (.546) 
Waist Circumference, cm 
 
0.017 (<.001) * 0.019 (<.001) * 
Total Sugar, grams 0.001 (.506) 0.000 (.838) 
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Abbreviations: White – non-Hispanic White, Mexican/Hispanic – Mexican or other Hispanic ethnicity, 
Black – Non-Hispanic Black, Other/Multi – other race or Multiracial WBC – white blood cell count,  
* significant at .05 
Unadjusted estimates from bivariate regression (unchanged from Table 3, provided for easy reference) 
Adjusted estimates controlled for age, sex, race, poverty-income ratio, smoking status, physical activity, 
use of cholesterol medication and waist circumference 
National estimates based on complex survey design 
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Table 2.5 
Unadjusted and Adjusted Estimates for the Association Between Net Carbohydrate Intake and 
Hemoglobin A1c  
Independent Variable Unadjusted 
β (p-value) 
Adjusted 
β (p-value) 
Age 
 
-.014 (.003) * -.010 (.038) * 
Sex 
 
  
     Male 
 
0.0 (Reference) 0.0 (Reference) 
     Female 
 
-0.272 (.012) * -0.246 (.016) * 
Race 
 
  
     White 
 
0.0 (Reference) 0.0 (Reference) 
     Mexican/Hispanic 
 
0.694 (<.001) * 0.696 (<.001) * 
     Black 
 
0.545 (<.001) * 0.522 (<.001) * 
     Asian 
 
0.151 (.206) 0.366 (.007) * 
     Other/Multi 
 
0.872 (.043) * 0.695 (.086) 
Poverty-Income Ratio 
 
-0.062 (.128) -0.025 (.486) 
Smoking 
 
  
     Non-Smoker 
 
0.0 (Reference) 0.0 (Reference) 
     Current smoker 
 
0.172 (.345) 0.033 (.809) 
Physical Activity   
     No 
 
0.0 (Reference) 0.0 (Reference) 
     Yes -0.309 (.025) * -0.304 (.016) * 
Waist Circumference, cm 
 
0.017 (.001) * 0.016 (<.001) * 
Total Net Carbohydrates, grams 
 
0.001 (.095) 0.001 (.311) 
Abbreviations: White – non-Hispanic White, Mexican/Hispanic – Mexican or other Hispanic ethnicity, 
Black – Non-Hispanic Black, Other/Multi – other race or Multiracial. *p<.05 
Unadjusted estimates from bivariate regression  
Adjusted estimates controlled for age, sex, race, poverty-income ratio, smoking status, physical activity, 
and waist circumference 
National estimates based on complex survey design 
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Table 2.6 
Unadjusted and Adjusted Estimates for the Association Between Total Sugar Intake and 
Hemoglobin A1c 
Independent Variable Unadjusted 
β (p-value) 
Adjusted  
β (p-value) 
Age 
 
-0.014 (.003) * -0.011 (.022) * 
Sex 
 
  
     Male 
 
0.0 (Reference) 0.0 (Reference) 
     Female 
 
-0.272 (.012) * -0.275 (.007) * 
Race 
 
  
     White 
 
0.0 (Reference) 0.0 (Reference) 
     Mexican/Hispanic 
 
0.634 (<.001) * 0.685 (<.001) * 
     Black 
 
0.545 (<.001) * 0.515 (<.001) * 
     Asian 
 
0.151 (.206) 0.349 (.010) * 
     Other/Multi 
 
0.872 (.043) * 0.698 (.080) 
Poverty-Income Ratio 
 
-0.062 (.128) -0.025 (.499) 
Smoking 
 
  
     Non-Smoker 
 
0.0 (Reference) 0.0 (Reference) 
     Current smoker 
 
0.172 (.345) 0.045 (.742) 
Physical Activity   
     No 
 
0.0 (Reference) 0.0 (Reference) 
     Yes 
 
-0.309 (.025) * -0.298 (.018) * 
Waist Circumference, cm 
 
0.017 (.001) * 0.016 (<.001) * 
Total Sugar, grams 
 
-0.000 (.924) -0.000 (.815) 
Abbreviations: White – non-Hispanic White, Mexican/Hispanic – Mexican or other Hispanic ethnicity, 
Black – Non-Hispanic Black, Other/Multi – other race or Multiracial, * p<.05 
Unadjusted estimates from bivariate regression (unchanged from Table 5 for easy reference) 
Adjusted estimates controlled for age, sex, race, poverty-income ratio, smoking status, physical activity, 
and waist circumference; National estimates based on complex survey design. 
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Figure 2.1  
Interaction Between Quintile of Net Carbohydrate Intake and Quintile of Waist Circumference 
on WBC in Adults with Diabetes 
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Figure 2.2 
Interaction Between Quintile of Net Carbohydrate Intake and Quintile of Waist Circumference 
on WBC in Males with Diabetes 
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Figure 2.3  
Interaction Between Quintile of Net Carbohydrate Intake and Quintile of Waist Circumference 
on WBC in Females with Diabetes 
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Chapter Five 
Effects of a Very Low-Carbohydrate Diet Versus a Dietary Approaches to Stop 
Hypertension Diet on Markers of Inflammation 
Introduction 
In the United States, the prevalence of diabetes in adults reached 13% in 2018 (U.S. 
Department of Health and Human Services, 2020). Prediabetes now affects approximately 35% 
of all adults (U.S. Department of Health and Human Services, 2020). Unfortunately, the 
prevalence of diabetes appears to be increasing, and current prevention efforts are not reversing 
the trend (Centers for Disease Control and Prevention, 2017; U.S. Department of Health and 
Human Services, 2020).    
Reducing chronic inflammation may be one method of addressing these increasing 
trends. Abdominal weight gain is implicated in the development of chronic inflammation. 
Visceral fat (adipose tissue within the abdominal cavity) is metabolically active and secretes 
inflammatory cytokines that have been implicated in the pathogenesis, progression and 
complications of type 2 diabetes (T2DM) (Donath & Shoelson, 2011; Panee, 2012; Rehman et 
al., 2017). In addition, Pedersen at al. (2015), recently linked increased insulin concentration 
with the development of inflammation. However, current treatment recommendations do not 
address inflammation and frequently use medications that increase insulin either by increasing 
endogenous insulin secretion (e.g. sulfonylureas), or through insulin injections (American 
Diabetes Association, 2020; Garber et al., 2020). One method of improving current prevention 
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and treatment strategies may be to address this chronic inflammation by identifying methods that 
simultaneously decrease glucose levels and inflammation. Diet may be one method of 
simultaneously decreasing both.  
This study supplemented a larger parent study, the Michigan, Hypertension, Diabetes, 
and Obesity Education Research Online (MHERO) trial, conducted by dissertation committee 
members Dr. L. Saslow and Dr. C. Richardson, and other co-investigators including a nurse (Dr. 
L. Jones), a pharmacist (Dr. H. Diez), and a public health researcher (Dr. J. Wolfson).  
The purpose of this supplementary study was to further understand the effect that diet, 
and its associated decrease of insulin, has on inflammation and diabetes outcomes. To that end, 
we used a dietary intervention comparing a very-low-carbohydrate (VLC) diet to a Dietary 
Approaches to Stop Hypertension (DASH) diet to study the relationship between insulin, 
inflammation and metabolic dysfunction. Finally, this research examined whether a VLC diet or 
a DASH diet decreased inflammation. 
Methods 
Research Design 
The present study utilized the protocol of the parent study. The parent study’s purpose 
was to use an interprofessional team to conduct a comparative effectiveness trial to compare a 
VLC diet to the DASH diet for overweight or obese adults with hypertension and prediabetes or 
T2DM. The Institute of Medicine defines comparative effectiveness trials as those that generate 
evidence to compare the benefits and harms of alternative methods to prevent, diagnose, or treat 
a clinical condition (Institute of Medicine, 2009). MHERO’s main aim was to test the feasibility, 
acceptability, and preliminary comparative efficacy of the diet intervention which will be 
determined by changes in the primary outcome of systolic blood pressure. Exploratory secondary 
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outcomes included weight, glycemic control, changes in glucose-lowering medications or 
antihypertensives, dietary adherence, quality of life, and diabetes-related distress. The parent-
study used a 2 x 2 factorial design based on diet type and level of support (standard support 
versus extra which provided additional education on coping and support strategies).  
The present study had a recruitment goal of 120 overweight or obese adults with 
hypertension and prediabetes or T2DM who would be randomized using a permuted block 
randomization process, to a 4-month VLC or DASH intervention. Furthermore, participants were 
stratified by body mass index (BMI; < 30 or ≥ 30) and gender (male or female). BMI and gender 
were chosen for stratification due to baseline and differential treatment effects that may be 
observed in these groups (Kennedy et al., 1997; Stommel & Schoenborn, 2010). The study team 
recruited potentially eligible participants from the University of Michigan health system. 
Participants received a letter describing the study and received follow-up phone calls. 
Inclusion criteria 
Participants were screened based on whether they met the inclusion criteria from their 
medical records from the past year or based on their self-report. The inclusion criteria were BMI 
of 25-50, diagnosis of hypertension (within the past 6 months); current resting systolic blood 
pressure of 130 mm Hg or higher (safety protocol in place for those with elevated blood pressure 
of 180 mmHg or higher and experiencing symptoms); diagnosis of either prediabetes or T2DM 
defined as a hemoglobin A1c (HbA1c) of 5.7% or higher or a two-hour glucose tolerance test 
greater than 140 mg/dL; aged 18-70 years old; access to the internet and text messaging, ability 
to engage in light physical activity, sufficient control over their food intake to adhere to study 
diets; willingness to regularly self-monitor blood pressure, glucose, dietary intake and body 
weight over the 4-month trial; participation in the trial approved by primary care provider along 
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with agreement to work with the participant and our research team to manage medication 
changes. 
Exclusion criteria 
 Exclusion criteria included: non-English speaking; current use of insulin, Dilantin, 
lithium, and warfarin; inability to complete baseline measurements; severe renal or hepatic 
insufficiency; cardiovascular dysfunction, including diagnosis of congestive heart failure, 
(angina, arrhythmias, cardiomyopathy, or valvular heart disease); uncontrolled psychiatric 
disorder; consumption of  greater than 30 alcoholic drinks per week; current chemotherapy 
treatment; pregnancy or plans to get pregnant in the next 12 months; breastfeeding or less than 6 
months postpartum; planned weight-loss surgery or previous bariatric surgery; vegan or 
vegetarian diet; currently enrolled in a weight-loss program or taking weight-loss supplements 
and unwilling to stop before enrolling; expecting to move out of the area within 12 months; and 
any other medical condition that may make either diet dangerous as determined by the study 
medical team. Due to the number of participants deemed ineligible due to cardiac history, 
MHERO submitted an IRB amendment to review cardiac history on a case-by-case basis with a 
study physician. 
The study team screened participants to ensure initial eligibility. Eligible participants 
received a link to complete the informed consent form. Following consent, participants 
completed a number of steps, including: (1) completing a baseline self-report survey, (2) a letter 
sent to their primary care provider to secure approval for participation, (3) logging into one 
online pre-randomization class (4) having their blood pressure, height, weight and waist 
circumference measured by the study team at the School of Nursing (5) answering two 24-hour 
food recall phone calls to assess eating habits with a trained dietician at the Michigan Nutrition 
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Obesity Research Center (6) going to the Michigan Clinical Research Unit (MCRU) to have their 
blood drawn, and (7) receiving a fibroscan (a noninvasive scan of the liver). Waist circumference 
measurement and the fibroscan were optional for participants. All other measures were required 
for enrollment in the study. Enrollment and the intervention were completed on a rolling basis. 
All outcomes were repeated at 4 months. Participants received their results free of charge.  
Intervention. MHERO randomized participants to one of four groups. The four groups included 
DASH diet with extra support (additional education on coping and support strategies), DASH 
diet with standard support, VLC with extra support and a VLC diet with standard support. 
MHERO stratified participants by BMI and gender among the four groups. Participants received 
appropriate links throughout the intervention from a HIPAA-compliant automated system. 
Weekly emails included coursework, a short survey to assess adherence and any health concerns, 
short embedded videos and downloadable handouts, links to external resources, as well as 
transcripts for videos for those participants unable or unwilling to watch.  
The VLC diet entailed restricting intake of non-fiber carbohydrates to 20-35 grams per 
day as such diets have been recommended in T2DM (Hallberg et al., 2018; Jonasson, Guldbrand, 
Lundberg, & Nystrom, 2014; Saslow et al., 2014; Saslow et al., 2017; Seshadri et al., 2004) for 
their ability to lower insulin levels and promote oxidation of free fatty acids from the adipose 
tissue for fuel in the form of beta-hydroxybutyrate (Hallberg et al., 2018). MHERO 
recommended participants in this diet arm to consume moderate protein between 80-120g 
(unchanged from prior to enrolling in the intervention unless their intakes were below 
recommended levels from the Institute of Medicine) (Trumbo, Schlicker, Yates, & Poos, 2002) 
and to obtain their remaining calories from fat. Foods generally included animal foods, cheeses, 
eggs, nuts, seeds, low-carbohydrate vegetables and fats. Educational materials encouraged 
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participants to avoid all trans fats or hydrogenated oils. Materials also recommended avoiding 
polyunsaturated oils or highly processed oils for cooking due to chemical changes that occur 
when they are heated past their smoke point. Recommended fats included olive oil, avocado oil, 
unrefined coconut oil, butter, ghee, animal fats, walnut oil, macadamia nut oil, and limited 
quantities of sesame-seed oil and flaxseed oil. Additionally, the study team recommended 
participants to increase magnesium intake if they experienced constipation or post-exercise 
cramps and to increase salt if they experienced dizziness while standing. 
 The DASH diet involved lowering sodium to less than 2300 milligrams per day and 
limiting fat intake to 20-30% of calories. Furthermore, the diet encouraged fruits and vegetables, 
lean meats and fish, whole grains and low-fat dairy. The diet focused on foods high in potassium, 
magnesium, and calcium while limiting foods high in saturated fat, oil and sugar (Sacks et al., 
2009). 
 Extra support. Half of participants in each diet group received additional education on 
coping and support strategies which included positive emotions, mindful eating, support for 
health information seeking and sharing, cooking practice, and behavior. 
 Core strategies (Standard Support). All participants received the core program which 
encompassed a comprehensive behavior change strategy to encourage and support participants 
making these changes. Topics and approaches in the program included: goals for the diet, 
physical activity, and sleep in the form of text messages, mailed materials, and menus. Other 
components included coaching; social support; dietary self-monitoring using a free online or 
mobile application; and body weight self-monitoring with a digital scale. Education consisted of 
16 online sessions. Education modules contained 5 to 20-minute-long videos and handouts and 
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links to websites as well. The core strategies used with all participants to assist them in behavior 
change were as follows: 
1. Goals for diet, physical activity, and sleep. Participants received goals for diet content and 
to aim for 7-9 hours of sleep per night. In addition, beginning in week 6, participants received 
recommendations to engage in moderate-level physical activity for at least 150 minutes per 
week.  
2. Text messages. Participants received text messages to assist them in achieving targeted 
behavior. Messages served as reminders, motivation, and education. 
3. Mailed materials. Participants received cookbooks at baseline, at one, and at three months to 
increase participants’ self-efficacy for trying and preparing new foods. 
4. Menus. Participants received written meal plans, and grocery lists. 
5. Coaching. Coaches were available for participant questions primarily via email, but at times 
also by phone. 
6. Social support. MHERO encouraged participation in existing online support groups. The use 
of existing groups was chosen so that participants could continue if desired once the study was 
complete. 
7. Dietary self-monitoring using a free online or mobile application. MHERO asked 
participants to track their dietary intake with MyFitnessPal. 
8. Body weight self-monitoring using a digital scale. MHERO asked participants to track their 
body weight with the digital cellularly-linked scale provided to them to upload their data. 
Safety and consultations with study experts. Because the intervention, if successful, 
could have lowered blood pressure and blood glucose, we required monitoring of blood pressure 
and glucose levels, especially for those at highest risk (those taking antihypertensives or glucose-
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lowering medications other than metformin). To that end, participants were provided a home 
blood pressure monitor and a home glucometer if they were on glucose-lowering medications 
other than metformin. Participants received information on when to contact their primary care 
provider as the system was not intended for urgent matters or to replace their primary care 
provider. During weekly videos participants were asked about symptoms and the previous 
weeks’ blood pressure and glucose levels. Study staff reviewed responses and sent MyChart 
messages to providers as needed.  
Measures 
This study utilized the following measurements from the parent study: fasting insulin and 
glucose (for Homeostatic Model Assessment 2 – Insulin Resistance [HOMA2-IR] calculation), 
height, weight and demographics. 
The present supplemental trial added the measurement of the following biomarkers: 
interleukin 6 (IL-6), interleukin 8 (IL-8), tumor necrosis factor-alpha (TNF-α), monocyte 
chemoattractant protein 1 (MCP-1), high-sensitivity C-Reactive Protein (hs-CRP), and white 
blood cell count (WBC). While these are all non-specific biomarkers, they were selected due to 
their proinflammatory role in the development, progression and long-term complications of 
T2DM (Jagannathan-Bogdan et al., 2011; Lowe et al., 2014; Panee, 2012; Rehman & Akash, 
2016; Rehman et al., 2017; Twig et al., 2013; Wang et al., 2013) and were central to the 
hypothesis that they will be reduced following the diet intervention.  
HOMA2-IR. HOMA2-IR was calculated from glucose in mmol/L and fasting insulin in 
pmol/L using the HOMA2 calculator available from the Diabetes Trials Unit (Diabetes Trials 
Unit, n.d.). The original HOMA provided an estimate of insulin resistance based on fasting 
plasma glucose and insulin. HOMA2 accounts for additional variations to provide a more 
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accurate estimate including hepatic and peripheral glucose resistance, insulin secretion at glucose 
concentrations above 180 mg/dL, and the effects of proinsulin. The use of the calculator over the 
formula available to calculate HOMA-IR, provides model-derived estimates versus the linear 
approximations from the formula (Diabetes Trials Unit, n.d.). 
Pro-inflammatory markers. 
IL-6. IL-6 is involved in development of insulin resistance and T2DM, in part by 
destruction of beta cells (Rehman et al., 2017). It is predominantly produced by adipocytes, but 
also by monocytes, endothelial cells, fibroblasts, skeletal muscle and macrophages (Makki, 
Froguel, & Wolowczuk, 2013; Rehman et al., 2017). Because IL-6 is also produced in skeletal 
muscle, it is released during exercise where it increases glucose uptake and has an anti-
inflammatory effect (Makki et al., 2013). Increased levels of IL-6 are also associated with sleep 
disturbance (Irwin, Olmstead, & Carroll, 2016).  
IL-8. IL-8 is a proinflammatory chemokine secreted by adipocytes, monocytes, 
macrophages, T-lymphocytes, endothelial and epidermal cells (Cimini et al., 2017). Higher 
levels of IL-8 are observed in diabetic subjects and are associated with reduced glycemic control 
(Cimini et al., 2017). 
TNF-α. TNF-α is secreted by adipocytes (Rehman & Akash, 2016) and macrophages 
(Kahn, Hull, & Utzschneider, 2006). It is implicated in the development of insulin resistance and 
alters the action of insulin in animals (Rehman & Akash, 2016).  
MCP-1. MCP-1 is a chemokine produced from hypertrophied adipocytes and thought to 
be responsible for some of the initial macrophage infiltration. A comprehensive review on MCP-
1 and diabetes found that hyperglycemia increases the production of MCP-1 and that it is 
associated with many of the long-term complications in diabetes (Panee, 2012). 
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High-sensitivity C-Reactive Protein (Hs-CRP). Hs-CRP is not a cytokine but is produced 
in the liver in response to inflammation (Wang et al., 2013). In prospective studies, CRP was 
associated with risk of T2DM (Wang et al., 2013). Sleep disturbance and shorter sleep duration 
also were associated with higher levels of CRP (Irwin et al., 2016). 
WBC. Higher levels within the normal range are observed in obese subjects with insulin 
resistance compared to obese subjects without it (Ryder et al., 2014). In addition, higher 
incidence of metabolic syndrome was observed when subjects in upper quartiles of total 
leukocyte count were compared to the lowest (Babio et al., 2013). Lymphocytes are also 
correlated with insulin levels (Ryder et al., 2014).  
Each of the analytes IL-6, IL-8, TNF-α, and MCP-1, were run in duplicate, and in batches 
to provide a mean value. For values reported as below assay detection level, we used the assay 
threshold numeric value. In addition, if the duplicate values differed by greater than 20%, a mean 
of the two values was used. If one of the duplicates was reported as 0, the value from the other 
run was used.  
Statistical Analysis 
The supplemental outcomes for this study were not the primary outcomes of the parent 
trial and were not powered. Supplementary outcomes were exploratory. We used linear mixed 
models to analyze group differences following the intervention for each outcome variable. The 
model included interactions between time, diet and level of support. The model also controlled 
for the stratifying variables sex and baseline BMI (modeled as a continuous variable); and 
included the random intercept of participant. Each inflammatory marker was log transformed 
(used as the outcome variable) due to the skewed nature of their distributions. The residuals were 
also examined to test the assumptions of the linear mixed models. Due to residuals greater than 
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an absolute value of two, a sensitivity analysis was conducted to test the effects of these 
observations. The Bonferroni correction for multiple comparisons was used to protect from type 
1 error due to the number of outcome measures being studied. While the parent trial examined 
the effects of varying levels of support, it was not pertinent to our research questions. Therefore, 
we collapsed the diet and level of support groups to diet group to increase power during 
comparison tests. Stata provides a post-estimation option called Margins to aid in understanding 
and interpreting model results. This option was used to provide the estimated marginal means 
(EMM) and to test the difference in differences. EMMs provide the estimated means based on 
the model at baseline and 4 months. The EMM values were used to calculate the change by diet 
group. The difference in difference compares the change observed in the VLC diet group to the 
change observed in the DASH diet group. Finally, we planned to analyze mediation using 
structural equation modeling if significant effects of diet on inflammation were observed. 
Mediation analyses seek to understand the mechanism behind observed relationships. Structural 
equation modeling is a statistical analysis technique used to analyze the structure of 
relationships, including the effects of mediation. We consulted a statistician for all statistical 
analyses. Stata version 16, College Station, TX, was used for all statistical analyses. 
Results 
 Recruitment occurred from January of 2019 through March of 2020. Results are from the 
79 participants enrolled through October 2019 of which 58 had completed the intervention. 
Summary characteristics for all participants, and by diet group at baseline, are presented in Table 
3.1. The sample was 64.56% female, 72.60% non-Hispanic White, 19.18% non-Hispanic Black, 
2.74% Asian, 5.48% Hispanic ethnicity, and had a mean age of 58.84.  
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The parent study found that the VLC diet was more effective at decreasing BMI (VLC at 
baseline vs. at 4 months was 35.59 vs.  33.11 kg/m2), compared to the DASH diet (EMM at 
baseline vs. at 4 months was 35.59 vs. 34.18 kg/m2), difference in difference for VLC compared 
to DASH = -1.08 kg/m2. The VLC diet was also more effective at decreasing HbA1c (VLC 
EMM at baseline vs. at 4 months was 6.08 vs. 5.72 %), compared to DASH (EMM at baseline 
vs. at 4 months was 6.08 vs. 6.01 %). The difference in difference for HbA1c in the VLC group 
compared to DASH is -.28%.  
The following are the results from the present supplemental trial. A sensitivity analysis 
was completed based on the absolute value of the residuals. Dropping the observations with 
residuals greater than an absolute value of two did not alter significance testing for any of our 
outcomes. Table 3.2 presents results from the analyses on all observations, including 
observations with high residuals. EMM results for this supplemental trial at baseline and 4 
months, difference within arm, and difference in difference are presented in Table 2. The VLC 
diet was more effective at reducing fasting insulin (VLC EMM at baseline vs. at 4 months was 
19.81 vs. 14.00 µU/mL), compared to DASH (EMM at baseline vs. at 4 months was 19.11, vs. 
17.16 µU/mL, p = .027). Similarly, VLC participants also experienced greater reductions in 
HOMA2-IR (EMM at baseline vs. 4 months was 2.62 vs. 1.85), compared to the DASH diet 
group (EMM at baseline vs. at 4 months was 2.55 vs. 2.29, p = .029). However, the effects on 
fasting insulin and HOMA2-IR were no longer significant when a Bonferroni adjustment for 
multiple comparisons was used. Participants in the VLC groups experienced a greater reduction 
in WBC (EMM at baseline vs. at 4 months was 6.32 vs. 5.98 K/uL) compared to the DASH diet 
groups (EMM at baseline vs. at 4 months was 5.87 vs. 6.24 K/uL, p = .004). This effect on WBC 
was the only outcome to remain significant after the Bonferroni adjustment for multiple 
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comparisons. The DASH diet group experienced a greater reduction in IL-6 (EMM at baseline 
vs. at 4 months was 2.15 vs. 1.69 pg/mL), compared to participants in the VLC group (EMM at 
baseline vs. at 4 months was 3.38 vs 3..69 pg/mL), and the difference in difference approached 
significance (VLC compared to DASH .77, p = .070). We did not observe significant differences 
between diet groups for the other inflammatory markers, before the Bonferroni-adjustment: hs-
CRP (VLC EMM at baseline vs. at 4 months was 5.26 vs. 5.37), compared to the DASH diet 
group (EMM at baseline vs. at 4 months was 3.13 vs. 3.08 mg/dL), IL-8 (VLC EMM at baseline 
vs. at 4 months was = 7.13, 8.09; DASH EMM at baseline vs. at 4 months was 4.77 vs. 4.40 
pg/mL ), TNF-α (VLC EMM at baseline vs. at 4 months was 4.68 vs. 5.44; DASH EMM at 
baseline vs. at 4 months was 4.01 vs. 4.73 pg/mL), MCP-1 (VLC EMM at baseline vs. at 4 
months was 345.27 vs. 393.59; DASH EMM at baseline vs. at 4 months was 387.09 vs. 362.59 
pg/mL). Figures 3.1-3.4 show the effects over time on outcomes by diet group. Figure 3.1 
illustrates fasting insulin, Figure 3.2 illustrates HOMA2-IR, Figure 3.3 illustrates WBC, and 
Figure 3.4 illustrates IL-6. We were unable to test whether insulin mediated the effect between 
diet and inflammation due to the small sample size and limited effects observed on inflammatory 
markers. 
Discussion 
 The VLC diet was more effective than the DASH diet at reducing WBC, which held after 
the Bonferroni-adjustment. However, the DASH diet resulted in a greater decrease in IL-6, 
although this relationship was not statistically significant. We did not observe significant 
between-group changes in other inflammatory markers. The VLC diet produced greater 
reductions in fasting insulin and HOMA2-IR, although this relationship did not hold after the 
Bonferroni-adjustment for multiple comparisons.  
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This study was a pilot trial and not powered to test these examined effects, so further 
powered trials are warranted. In addition, the full recruitment of 120 subjects was not achieved. 
Additionally, the trial had a duration of 4 months, which may not have provided adequate time to 
observe an effect on inflammation. However, previous trials have observed effects on 
inflammation following interventions of 4 months or less (Al-Sarraj, Saadi, Calle, Volek, & 
Fernandez, 2009; Forsythe et al., 2008a). This may be due to the study population used. Some 
trials with effects observed within 4 months utilized participants with fewer comorbidities. For 
example, Forsythe et al. (2008a) decreased CRP, TNF-α, IL-6, IL-8 and MCP-1, in a sample of 
overweight men and women with dyslipidemia using a very low-carbohydrate diet for 12 weeks. 
That trial utilized in-person weekly visits with a Registered Dietitian (Forsythe et al., 2008a). 
Therefore, the method of education (in-person versus online), education level of the 
coach/educator, or health of the participants may be responsible for the differences observed. 
Additionally, Al-Sarraj et al. (2009) decreased CRP, TNF-α, ICAM-1, and MCP-1 at 6 weeks in 
a population with metabolic syndrome using a carbohydrate-restricted diet of 20-25% 
carbohydrate. That trial also used Registered Dieticians and in-person visits. Previous research 
suggests that longer trials may be needed to observe effects on inflammatory markers in a sample 
of adults with diabetes. For example, in Hallberg et al. (2018) hs-CRP was measured at 70 days 
and one year in their trial utilizing a very-low carbohydrate diet intervention to the standard of 
care for one year. Differences were observed in the ability of the intervention to produce an 
effect based on the intensity of the intervention. At 70 days, significant decreases in hs-CRP 
were not observed in any group, although effects were observed in all arms at one year (Hallberg 
et al., 2018). The present trial was an online trial, designed to be scalable and cost-effective. 
Therefore, an important next step would be to investigate whether such a low-resource trial may 
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provide similar effects on inflammation over a longer time period. Additionally, the three trials 
outlined above had good dietary adherence. As the parent trial is ongoing, dietary adherence data 
are not yet available, but in the future may yield insight into the results obtained from a lower 
resource trial in overweight or obese participants with prediabetes or T2DM and hypertension. 
Additionally, the VLC diet tended to produce larger reductions in fasting insulin and 
insulin resistance compared to the DASH diet, which was consistent with the hypothesis due to 
the decreased carbohydrate load of the VLC diet. However, there were inconsistent results when 
examining the effect of diet on inflammation. The VLC arm was more effective at significantly 
decreasing WBC, while the DASH arm appeared more effective at decreasing IL-6, although the 
difference did not reach statistical significance. However, IL-6 is also produced in skeletal 
muscle during exercise (Pedersen, Steensberg, & Schjerling, 2001), so potential differences in 
exercise may account for observed differences. The DASH diet provided a stronger emphasis on 
consuming fruits and vegetables, an effective approach at decreasing inflammation (Mahoney & 
Loprinzi, 2014). The DASH diet also promoted the intake of magnesium, which may also 
decrease inflammation (Chacko et al., 2010). The VLC diet emphasized limiting vegetable 
consumption to low-carbohydrate vegetables but did not provide specific recommendations to 
consume a minimum number of servings daily. It may be more effective to promote a minimum 
consumption of low-carbohydrate vegetables in the VLC diet as well to ensure that certain anti-
inflammatory nutrients such as magnesium are consumed in adequate amounts. A diet that 
combines the more effective attributes of each diet may be more effective at simultaneously 
decreasing fasting insulin, insulin resistance, and inflammation. 
A weight loss of 10% may be needed to decrease inflammation (Forsythe, Wallace, & 
Livingstone, 2008b). We hypothesized that the reduction of insulin would mediate a reduction in 
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inflammation, separate from the effects of weight loss. However, due to the limited sample size 
and short duration, we were unable to test this hypothesis. As the VLC group experienced a 
greater reduction in fasting insulin, and WBC was the only inflammatory marker to experience a 
significant reduction following the Bonferroni-adjustment, this relationship needs further 
investigation. Future trials would benefit from a larger sample and longer duration to test the 
effect of insulin in mediating this relationship between diet and inflammation. 
The limitations in the present study reflect the limitations of pilot studies in general. We 
had a small sample size and a treatment duration limited to 4 months. Additionally, we 
experienced problems with recruitment due to the requirement for a systolic blood pressure 
above 130 mmHg (with or without current use of  antihypertensive medications). While this 
minimum systolic blood pressure was used to stay consistent with the current American Heart 
Association goals for blood pressure control (Whelton et al., 2017), 97 participants were 
excluded due to this requirement. Future trials should alter this exclusion to aid in recruitment.  
The VLC diet was more effective at decreasing WBC, which remained significant after 
the Bonferroni adjustment. However, the DASH group tended to be more effective at decreasing 
IL-6, although this was not statistically significant. The VLC diet tended to be more effective at 
decreasing both fasting insulin and insulin resistance. Future trials of longer duration and larger 
sample sizes are needed to evaluate the effectiveness of these diets at decreasing insulin and 
inflammation, and whether insulin is partially mediating this relationship.  
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Table 3.1  
Summary Characteristics of Participants at Baseline 
Variable All VLC DASH 
Gender, N (%)    
     Female 51 (64.56) 24 (63.16) 27 (65.85) 
     Male 28 (35.44) 14 (36.84) 14 (34.15) 
Race/Ethnicity, N (%)    
     White 53 (72.60) 26 (76.47) 27 (69.23) 
     Black 14 (19.18) 6 (17.65) 8 (20.51) 
     Asian 2 (2.74) 0 (0) 2 (5.13) 
     Hispanic 4 (5.48) 2 (5.88) 2 (5.13) 
Age years, Mean (SD) 58.84 (7.95) 57.61 (9.17) 59.98 (6.53) 
Baseline BMI kg/m2, 
Mean (SD) 
35.88 (5.58) 35.48 (5.42) 36.24 (5.76) 
Baseline Glucose 
mg/dL, Median (IQR) 
109.00 (101.00, 
115.00) 
106.50 (96.00, 113.00) 111.00 (102.00, 
118.00) 
Baseline HbA1c%, 
Median (IQR) 
6.00 (5.80, 6.30) 6.00 (5.80, 6.30) 6.00 (5.70, 6.30) 
Abbreviations: N – number, SD – standard deviation, IQR – interquartile range, White – non-Hispanic 
White, Black – non-Hispanic Black 
Means and SD used for normal distributions, Median and IQR used for skewed distributions 
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Table 3.2  
Comparison of DASH Diet to VLC Diet Change Relative to Baseline 
Outcome 
Variable 
 
Baseline 
EMM (SE) 
 4 months 
EMM (SE) 
Difference 
Within 
Diet Arm 
Difference 
in 
Difference 
Difference in 
Difference 
P-value 
Fasting Insulin 
µU/mL 
   -3.86 .027 
     VLC 19.81 (1.47) 14.00 (1.13) -5.81   
     DASH  19.11 (1.35) 17.16 (1.34) -1.95   
HOMA2-IR    -0.51 .029 
     VLC 2.62 (0.19) 1.85 (0.15) -0.77   
     DASH 2.55 (0.18) 2.29 (0.18) -0.26   
Hs-CRP mg/dL    0.16 .864 
     VLC 5.26 (0.80) 5.37 (0.89) 0.11   
     DASH 3.13 (0.45) 3.08 (0.50) -0.05   
IL-6 pg/mL    0.77 .070 
     VLC 3.38 (1.03) 3.69 (1.13) 0.31   
     DASH  2.15 (0.64) 1.69 (0.52) -0.46   
IL-8 pg/mL    1.32 .090 
     VLC 7.13 (1.24) 8.09 (1.45) 0.96   
     DASH  4.77 (0.84) 4.40 (0.78) -0.37   
TNF-α pg/mL    0.04 .94 
     VLC 4.68 (0.40) 5.44 (0.51) 0.76   
     DASH  4.01 (0.33) 4.73 (0.44) 0.72   
MCP-1 pg/mL    72.82 .092 
     VLC 345.27 (26.96) 393.59 (33.52) 48.32   
     DASH  387.09 (29.07) 362.59 (30.83) -24.5   
WBC K/uL    -0.72 .004* 
    VLC 6.32 (0.25) 5.98 (0.22) -.33   
     DASH  5.87 (0.23) 6.24 (0.23) .37   
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EMM – estimated marginal mean, SE – standard error 
* significance held after Bonferroni adjustment for multiple comparisons 
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Figure 3.1  
Change in Fasting Insulin over 4-Month Intervention by Diet Group 
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Figure 3.2  
Change in HOMA2-IR over 4-Month Intervention by Diet Group 
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Figure 3.3  
Change in WBC over 4-Month Intervention by Diet Group 
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Figure 3.4 
Change in IL-6 Over 4-Month Intervention by Diet Group 
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Chapter Six 
Discussion 
In the United States, there are over 100 million adults diagnosed with prediabetes or type 
2 diabetes (T2DM) (U.S. Department of Health and Human Services, 2020). Hyperglycemia and 
insulin resistance are key defects in T2DM (Wilcox, 2005). Inflammation is involved in the 
pathogenesis (Donath & Shoelson, 2011), progression (Rehman et al., 2017), and long-term 
complications of T2DM (Panee, 2012). However, current recommendations do not include goals 
for decreasing inflammation (American Diabetes Association, 2020; Garber et al., 2020). The 
pathogenesis of inflammation in prediabetes and T2DM is likely multifactorial and may vary 
based on stage of disease progression. Hyperglycemia and visceral adipose tissue, which are both 
common in individuals with T2DM, are both proinflammatory (Jafar, Edriss, & Nugent, 2016; 
Makki, Froguel, & Wolowczuk, 2013). However, previous research also suggests that 
hyperinsulinemia is associated with the development of inflammation (Pedersen et al., 2015). 
Diets capable of simultaneously decreasing insulin and glucose levels may improve the outcomes 
for those diagnosed with, and at risk for, T2DM. Overall, this dissertation has sought to increase 
our understanding of the effect of diet on inflammation, and the role of insulin as a mediator in 
this pathway.  
Results 
Aim 1 - Association Between Fasting Insulin and High-Sensitivity C-Reactive Protein Among 
Adults Without Diabetes: NHANES 2005-2010
 
 
  143 
 
Examine the association between fasting insulin and high-sensitivity C-reactive protein 
(hs-CRP), a marker of inflammation, using the National Health and Nutrition Examination 
Survey (NHANES), 2005-2010. I hypothesized the existence of a significant positive association 
between fasting insulin and hs-CRP. 
Findings.  This analysis was completed on a sample of adults without a diagnosis of 
diabetes. A sample without diabetes was selected due to the effects of hyperglycemia, beta cell 
failure, and glucose-lowering medications effect on insulin levels that would occur in a sample 
with diabetes. After adjusting for age, race, gender, smoking status, physical activity, and 
poverty-income ratio, fasting insulin level was significantly associated with high-risk hs-CRP 
compared to average-risk hs-CRP (RRR 1.07, p < .001). While adjusting for the same covariates 
and waist circumference, the RRR was reduced to 1.02, p = .002. Thus, the inclusion of waist 
circumference as a covariate attenuated the association between fasting insulin and high-risk hs-
CRP by 68%, indicating some role of visceral adipose tissue in mediating the relationship 
between fasting insulin and hs-CRP. We also found a significant association between fasting 
insulin and low-risk hs-CRP compared to average risk hs-CRP in both the reduced adjusted 
model (β = 0.91, p < .001) and the full adjusted model (β = 0.91, p < .001). The relationship 
between fasting insulin and low-risk hs-CRP was attenuated 69% between the full and the 
reduced models. 
 Conclusions. There was a significant association between fasting insulin and hs-CRP 
which was only partially mediated by waist circumference. Treatment approaches that 
simultaneously decrease insulin while achieving glycemic control may decrease inflammation. 
Aim 2 – Association Between Net Carbohydrate and Sugar Intake on Inflammation and 
Hemoglobin A1c in Adults with Diabetes 
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Examine the association between net carbohydrate and sugar intake on white blood cell 
count at the upper end of the normal range, another indicator of inflammation, and HbA1c, using 
the National Health and Nutrition Examination Survey, 2011-2016. I hypothesized the existence 
of a significant positive association between net carbohydrate and sugar intake and white blood 
cell count (WBC) and on hemoglobin A1c (HbA1c). 
Findings. This analysis was completed in a sample of adults with a diagnosis of diabetes and 
provided national estimates. Most participants were using glucose-lowering medications, 61.71% 
oral medications and 19.12% were using insulin. The first two models examined the effect of 
diet (net carbohydrate or total sugar) on WBC. After adjusting for age, sex, race, poverty-income 
ratio, smoking status, physical activity, use of cholesterol medication, and waist circumference, 
there was a moderate but significant association between net carbohydrate intake and WBC (β = 
0.001, p = .047). However, after adjusting for the same confounders, there was no association 
between total sugar intake and WBC (β = 0.000, p = .838). The next two models examined the 
effect of diet (net carbohydrate versus total sugar) on HbA1c. In the adjusted model which 
controlled for age, sex, race, poverty-income ratio, smoking status, physical activity and waist 
circumference, neither total net carbohydrates (β = 0.001, p = .311) nor total sugar (β = -0.000, p 
= .815), were associated with HbA1c.  
 Conclusions. There was a significant association between net carbohydrate intake and 
WBC concentration at the higher end of the normal range, which suggests that decreasing 
carbohydrate load may decrease inflammation. 
Aim 3 – Effects of a Very Low-Carbohydrate Diet Versus a Dietary Approaches to Stop 
Hypertension Diet on Markers of Inflammation 
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(a) Compare the effects of a very low-carbohydrate diet (VLC) and a Dietary Approaches 
to Stop Hypertension diet (DASH), on fasting insulin, insulin resistance, and inflammatory 
markers. Based on suggestive evidence from previously conducted literature (Al-Sarraj, Saadi, 
Calle, Volek, & Fernandez, 2009; Asemi, Samimi, Tabassi, Sabihi, & Esmaillzadeh, 2013; 
Hallberg et al., 2018; Jonasson, Guldbrand, Lundberg, & Nystrom, 2014; Shirani, Salehi-
Abargouei, & Azadbakht, 2013; Steckhan et al., 2016), I hypothesized the existence of clinically 
significant improvements insulin, insulin resistance, and inflammatory markers for participants 
assigned to a VLC diet, compared to lesser improvements for those assigned to the DASH diet 
arm. (b) Examine whether VLC- or DASH-associated changes in fasting insulin mediate the 
effect of diet on inflammatory markers IL-6, IL-8, TNF-α, MCP-1, hs-CRP, or WBC count. I 
hypothesized the existence of a significant positive association between fasting insulin and 
dietary effect on inflammation.  
Findings 3a. This study was carried out in a sample of overweight or obese adults with 
hypertension and prediabetes or T2DM. Overall, the VLC diet tended to be more effective at 
reducing fasting insulin (VLC EMM at baseline vs. at 4 months was 19.81 vs. 14.00 µU/mL), 
compared to DASH (EMM at baseline vs. at 4 months was 19.11 vs. 17.16 µU/mL, p = .027) , 
and HOMA2-IR (VLC EMM at baseline vs. at 4 months was 2.62 vs. 1.85), compared to the 
DASH diet group (EMM at baseline vs. at 4 months was 2.55 vs. 2.29, p = .029). However, the 
effects on fasting insulin and HOMA2-IR were no longer significant after a Bonferroni 
adjustment for multiple comparisons. The VLC group experienced greater and significant 
reductions in the inflammatory marker of WBC counts at the upper end of the normal range 
(EMM at baseline vs. at 4 months was 6.32 vs. 5.98 K/uL) compared to the DASH diet group 
(EMM at baseline vs. at 4 months was 5.87 vs. 6.24 K/uL, p = .004), which remained after the 
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Bonferroni adjustment for multiple comparisons. The DASH diet group experienced greater 
reductions in IL-6 (EMM at baseline vs. at 4 months was 2.15 vs. 1.69 pg/mL), compared to 
participants in the VLC group (EMM at baseline vs. at 4 months was 3.38 vs. 3.69 pg/mL), 
which approached significance (VLC compared to DASH .77, p = .070). Significant differences 
between diet groups were not observed for the other inflammatory markers before the 
Bonferroni-adjustment. The direct inflammatory measure of WBC counts was the only outcome 
to remain significant after the Bonferroni adjustment for multiple comparisons. 
Conclusions. The VLC diet was more effective at decreasing WBC and tended to be 
more effective at decreasing fasting insulin and insulin resistance. However, the DASH diet 
tended to be more effective at decreasing IL-6.  
Findings 3b. We were unable to test whether insulin mediated the effect between diet 
and inflammation due to the small sample size and limited effects observed on inflammatory 
markers. 
Limitations 
There were several limitations to these studies. Two of the trials utilized cross-sectional 
NHANES data, which do not allow the inference of cause and effect. Additionally, the study 
examining the effect of net carbohydrate and sugar intake (Aim 2) used aggregate dietary data. 
This prevented us from distinguishing between added sugar and naturally occurring sugar, and 
between whole grains versus highly refined carbohydrates. Previous research suggests that added 
sugar may be more proinflammatory than naturally present sugar, and that glycemic index or 
glycemic load may impact the inflammatory response. Therefore, this was a limitation in Aim 2 
(Aeberli et al., 2011; DiNicolantonio, Mehta, Onkaramurthy, & O'Keefe, 2018; O'Keefe, 
Gheewala, & O'Keefe, 2008). 
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In the final Aim 3 study we were limited by a small sample size as we experienced 
problems with recruitment due to the requirement for a systolic blood pressure above 130 mmHg 
(with or without current use of antihypertensive medications). Moreover, this study had a 
treatment duration of just four months. While effects on inflammation have been observed in 4-
month trials in populations with fewer comorbidities (Al-Sarraj et al., 2009; Forsythe et al., 
2008), a longer duration may be needed in individuals diagnosed with T2DM (Hallberg et al., 
2018). The study used in Aim 3 was not powered to test effects and the outcomes analyzed were 
exploratory. 
Clinical and Policy Implications 
 Current standards of care for the treatment of T2DM do not provide recommendations for 
decreasing inflammation (American Diabetes Association, 2020; Garber et al., 2020). However, 
there is evidence that inflammation is involved in the long-term complications of T2DM. This 
has important implications, both economic and related to quality of life. In 2017, direct and 
indirect costs of diagnosed diabetes was 327 billion (U.S. Department of Health and Human 
Services, 2020). Cost-analyses of diabetes suggest that the majority of spending related to 
diabetes care was for the treatment of advanced complications in older adults (Herman, 2013). A 
breakdown of these costs found that hospital inpatient visits, nursing homes, hospice care, home 
health care, and prescriptions medications for complications of diabetes accounted for almost 
three-quarters of health care expenditures (Herman, 2013).  
Additionally, the most recent report from the CDC on the current state of diabetes in the 
US found that 50% of adults with diabetes had an A1c above 7% (U.S. Department of Health 
and Human Services, 2020). Current treatment recommendations from the American Diabetes 
Association (ADA) recommend a goal HbA1c of less than 7%. Therefore, current treatment 
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approaches are not effective for approximately half of US adults with diabetes. The cost of 
medications may be one barrier to treatment. The ADA issued a report on the economic impact 
of diabetes in 2017 (Yang et al., 2018). The cost of medications has increased by 45% from 2012 
to 2017, after adjusting for inflation (Yang et al., 2018). Results from the National Health 
Interview Survey suggest cost is a barrier to Americans receiving the medications necessary to 
control their blood sugar (Knight, Probst, Liese, Sercye, & Jones, 2016). The survey asked four 
questions about altered medication use related to cost and 18.9% of participants with diabetes 
responded yes to at least one question (Knight et al., 2016). Reducing the carbohydrate load or 
postprandial glycemic excursions would likely decrease the need for glucose-lowering 
medications. Trials have documented success of needing lower doses or eliminating the use of 
glucose-lowering medications altogether, including insulin injections by decreasing the 
carbohydrate load (Hallberg et al., 2018). This may prove a more viable option for those who are 
unable to pay for medications. 
To address this issue, we need to address the deficiencies in current recommendations. 
Addressing chronic inflammation and setting goals to control it would be an important first step. 
Secondly, effective diet interventions capable of simultaneously decreasing glucose levels and 
inflammation need to be investigated and disseminated.  
Conclusions 
The current treatment recommendations for T2DM do not address the benefit of 
decreasing inflammation (American Diabetes Association, 2020; Garber et al., 2020). However, 
there is evidence, including from our study, that prevention and treatment efforts may be 
improved if this is addressed. These results suggest that treatment approaches that 
simultaneously decrease insulin levels while achieving glycemic control may provide additional 
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anti-inflammatory effects, and therefore may improve long-term outcomes for adults with 
T2DM. As carbohydrates are the predominant macronutrient responsible for postprandial 
glucose excursions and insulin response (Evert et al., 2019), reducing carbohydrate load may 
improve glycemic control while simultaneously decreasing inflammation. 
Future Research 
 Future trials of longer duration and larger samples are needed to evaluate the 
effectiveness of diet at decreasing insulin and inflammation, and whether insulin is partially 
mediating this relationship. Additionally, understanding how postprandial glucose excursions 
impact inflammation both in the short- and long-term will increase our understanding of the 
effect so that dietary guidelines may provide more nuanced recommendations 
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